Welcome to STN International! Enter x:X

LOGINID:sssptase11626

```
PASSWORD:
```

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * *	* *	* *	* *	* Welcome to STN International * * * * * * * * * *
NEWS	1			Web Page for STN Seminar Schedule - N. America
NEWS	2	JUL		CA/CAplus patent coverage enhanced
NEWS	3	JUL	28	EPFULL enhanced with additional legal status
NITT O			0.0	information from the epoline Register
NEWS	4 5	JUL		IFICDB, IFIPAT, and IFIUDB reloaded with enhancements STN Viewer performance improved
NEWS	6	AUG		INPADOCDB and INPAFAMDB coverage enhanced
NEWS	7	AUG		CA/CAplus enhanced with printed Chemical Abstracts
				page images from 1967-1998
NEWS	8	AUG	15	CAOLD to be discontinued on December 31, 2008
NEWS		AUG		CAplus currency for Korean patents enhanced
NEWS	10	AUG	27	CAS definition of basic patents expanded to ensure
				comprehensive access to substance and sequence
NEWS	11	SEP	1.0	information Support for STN Express, Versions 6.01 and earlier,
MEND	11	OLL	10	to be discontinued
NEWS	12	SEP	25	CA/CAplus current-awareness alert options enhanced
				to accommodate supplemental CAS indexing of
				exemplified prophetic substances
NEWS	13	SEP	26	WPIDS, WPINDEX, and WPIX coverage of Chinese and
				and Korean patents enhanced
NEWS		SEP		IFICLS enhanced with new super search field EMBASE and EMBAL enhanced with new search and
NEWS	13	SEP	29	display fields
NEWS	16	SEP	30	CAS patent coverage enhanced to include exemplified
				prophetic substances identified in new Japanese-
				language patents
NEWS		OCT		EPFULL enhanced with full implementation of EPC2000
NEWS	18	OCT	07	Multiple databases enhanced for more flexible patent
NEWS	2.0	OCT	22	number searching Current-awareness alert (SDI) setup and editing
NEWS	19	OCI	22	enhanced
NEWS	20	OCT	22	WPIDS, WPINDEX, and WPIX enhanced with Canadian PCT
				Applications
NEWS	21	OCT	24	CHEMLIST enhanced with intermediate list of
				pre-registered REACH substances
NEWS	EXP	RESS		E 27 08 CURRENT WINDOWS VERSION IS V8.3, CURRENT DISCOVER FILE IS DATED 23 JUNE 2008.
			MND	CORRENT DISCOVER FILE IS DATED 23 JUNE 2006.
NEWS	HOUR	RS	STI	V Operating Hours Plus Help Desk Availability
NEWS				lcome Banner and News Items
NEWS	IPC8	3	For	general information regarding STN implementation of IPC

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

FILE 'HOME' ENTERED AT 13:08:13 ON 18 NOV 2008

=> fil reg

 COST IN U.S. DOLLARS
 SINCE FILE
 TOTAL

 BNTRY
 SESSION

 FULL ESTIMATED COST
 0.21
 0.21

FILE 'REGISTRY' ENTERED AT 13:08:32 ON 18 NOV 2008 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT. PLEASE SEE "HELP USAGETERMS" FOR DETAILS. COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 16 NOV 2008 HIGHEST RN 1072892-84-2 DICTIONARY FILE UPDATES: 16 NOV 2008 HIGHEST RN 1072892-84-2

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH July 5, 2008.

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>

Uploading C:\Program Files\STNEXP\Oueries\10517264.str

chain nodes:
10
ring nodes:
1 2 3 4 5 6 7 8 9
ring bonds:
1-2 1-6 2-3 2-7 3-4 3-9 4-5 5-6 7-8 8-9
exact/norm bonds:
2-3 2-7 3-9 7-8 8-9
normalized bonds:
1-2 1-6 3-4 4-5 5-6

Match level: 1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:CLASS 11:Atom

L1 STRUCTURE UPLOADED

=> d L1 HAS NO ANSWERS L1 STR

N

Structure attributes must be viewed using STN Express query preparation.

=> s 11 SAMPLE SEARCH INITIATED 13:08:49 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 47727 TO ITERATE

4.2% PROCESSED 2000 ITERATIONS INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED) 50 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**

PROJECTED ITERATIONS: 941495 TO 967585
PROJECTED ANSWERS: 131546 TO 141452

L2 50 SEA SSS SAM L1

=> s 11 full

FULL SCREEN SEARCH COMPLETED - 951522 TO ITERATE

100.0% PROCESSED 951522 ITERATIONS SEARCH TIME: 00.00.16 136136 ANSWERS

DEFINION 1111E. 00.00.10

L3 136136 SEA SSS FUL L1

=> fil caplus

COST IN U.S. DOLLARS SINCE FILE TOTAL ENTRY SESSION

FULL ESTIMATED COST 178.36 178.57

FILE 'CAPLUS' ENTERED AT 13:09:18 ON 18 NOV 2008

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT. PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is

held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 18 Nov 2008 VOL 149 ISS 21 FILE LAST UPDATED: 17 Nov 2008 (20081117/ED)

Caplus now includes complete International Patent Classification (IPC) reclassification data for the third quarter of 2008.

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

http://www.cas.org/legal/infopolicy.html

=> s 13 L4 38569 L3

=>

L8

=> s 14 and pharmaceutical 316557 PHARMACEUTICAL 92562 PHARMACEUTICALS

371957 PHARMACEUTICAL
(PHARMACEUTICAL OR PHARMACEUTICALS)

L5 3160 L4 AND PHARMACEUTICAL

=> s 15 and arthritis

54947 ARTHRITIS 2 ARTHRITISES 54947 ARTHRITIS

(ARTHRITIS OR ARTHRITISES)

L6 214 L5 AND ARTHRITIS

=> s 16 and rheumatoid

39150 RHEUMATOID 11 RHEUMATOIDS 39154 RHEUMATOID

(RHEUMATOID OR RHEUMATOIDS)

154 L6 AND RHEUMATOID

=> s 17 and cytokine 120584 CYTOKINE

158413 CYTOKINES 209557 CYTOKINE (CYTOKINE OR CYTOKINES)

20 L7 AND CYTOKINE

=> d ibib abs hitstr tot

THE ESTIMATED COST FOR THIS REQUEST IS 109.00 U.S. DOLLARS DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N:y

149:190139 Compupates of anti-CD70 antibodies with drugs and their use for the treatment of cancer and limite aw, Che-Leung; Momarchern, Julie; Brachman, Jonathan

PATERT ASSIGNEE(S): G. Seattle Genetics, Inc., USA U.S. Pat. Appl. Pebl., Sipp., Cont.-in-part of U.S. Ser. No. 546,384. CODEN: USENCO

DOCUMENT TYPE:

FAMILY ACC. NEW, COUNTY

ATENT	11	arca.	MATI	CRI :														
						KIN		DATE										
9	8 :	2008	0736	999 56		Al A2		2004	0131		05.2	007-		76		2	0070	413
		2004	0736	54		A3 A2		2003	0301									
		381	CER, CE, LK, EW, EG, NC,	CO, CH, CH, CH,	CH, CM, CM, CY,	AM, CU, EK, LT, KE, CZ, RO, NK,	CE, BU, LU, LS, DE,	DE, ID, LV, NW, DK,	DK, IL, MA, ME, EE, SK,	IM, IN, MD, ED, ES, TR,	DE, IS, NG, SL, FI,	EC, JP, MK, SE, FR,	KE, KE, MN, TE, GB,	NO, NO, UO, GR,	ES, KP, MX, ZM, HU,	FI, KE, ME, ZM, IE,	CB, KE, NA, AT, IT,	CD, LC, NI BE, LU,
RIORI			0233	79.4		83		2006			08 2	003-	4490	55 P		P 2	0050 0030 0040	220
											US 2	005-	5463	04		A2 2	0050	819

Conjugates of antibodies to CDTO antigens and sytotoxic compds. that can be used to treat diseases associated with aberrant presentation of the antigens, including cancers and immune disorders, are described.

Testings, including occurs and improve discounts, are wars unexor anisohom properties with satisfaction force in described. The
or anisohom properties of the satisfaction of the satisfaction of the
exceptability model of multiple enlesses and delablates times quows to a
first of the satisfaction amountain monocoleta
like Testing of the satisfaction of the satisf

NUS COMPRISET 2008 MCS on STM
2001: 10777 CASADYS
2001: 10777 CASADYS
PROPRISED AND ASSOCIATION OF THE PROPRISED ASS

INVENTOR(S): PATENT ASSIGNAL(S):

DOCUMENT TYPE: LANGUAGE: FAMILY ACC. NIM. COUNT: PATENT INFORMATION:

| Description | Property | Proper

OTHER SOURCE(S): MARRAT 148:168736

ANSMER 1 OF 20 CAPLUS COPYRIGHT 2000 ACS on STN [Continued]

ARREAS JO 20 CABLUS CONTRIBE 2000 ACC ON STM (Contained between the contained between the contained between the contained above the contained abov

of pharmaceutical compus. for the prophylaxis and/or treatment of diseases which can be influenced by the inhibition of the kinase activity of Nnkl and/or Nnkl (Nnkla or Nnklb) and/or variants these The investice compds. were evaluated for their kinase inhibitory

Tity.

It has been shown that the particular preferred compd. of the invention exhibited IC50 values below 10 pM in in vitro biological screening assays for inhibition of Mnkl and/or Mnk2 kinase activity. I should

for the transmiss of in particular methods diseases of the tiple and destrohydate metals and the consecutive complications and diseases. 14073-64-7, inclinations (14073-64-7, inclination) (15073-64-7)

preparation of novel pyrelogyrandide compds. useful in prophylazia, most clim thorapy of diseases which can be safteened by substitute of their control and activaty) 14(40)-464-05-050, control activaty) 11(40)-464-050, control activation of their control activaty) 11(40)-464-050, control activation of their control activaty) 11(40)-464-050, control activation of their control activation acti

JS COPYRIGHT 2008 ACS on STM 2007:1175935 CAPLIS 147:480410 LS AMENUS 3 OF 20 CAPLU ACCESSION NUMBER: 2

PATERT ASSIGNED(S):

DOCUMENT TYPE: LANGUAGE: FAMILY ACC; NIM; COUNT: FATENT INFORMATION:

PATERT				KIR		DATE			APP2	ICAT					ATE	
NO 2001				A3					WO 2			86				
Wit	AL,	NG,				AU,	AZ,	BA,	nn,	BG,	BH,	BR,	IN.	BY,	RZ,	CA
	CH,	CN,	00,	CR,		CZ,	DE,	DK,	Ted,	DZ,	EC,	EE,	EG,	ES,	FI,	CIR
	GD,	GE,	GH,	CN,	97,	HN,	HR,	HU,	ID,	IL,	IN,	IS,	JP,	KE,	103,	320
	721,	KP,	KR,	KZ,	13,	LC,	LK,	LR,	LS,		LU,	LY.	MA,	MD,	MG,	NX.
	MRI.	NW.	NK.	MY.	MS,	10%	193.	NI.	NO.	NE.	CN.	PG.	PH.	12.	27.	BO
	33.	377.	80,	SD,	SE,	80,	88.	81.	521,	SV.	SY.	75.	TH.	TH.	TE.	77
						VC,										
2811	AT.	BE,	BG,	CH,	CY,	CZ,	DE,	DK,	EE,	ES,	FI,	PE,	CB,	GE,	BU.	IE
	IS,	17,	LT,	LU,	LV,	MC,	MT,	ML,	PL,	PT,	no,	SE,	SI,	SIX,	TR,	BF
	BJ,	CF,	cg,	CI,	CM,	CA,	GH,	90,	CM,	ML,	MR,	NE.	SIN,	TD,	TG,	TO

GR, GM, KE, LS, NW, ME, NA, SD, SL, SE, SY, KG, KE, ND, NU, TJ, TM
PRIORITY APPLIE. INFO.: EP 2006-7454

PRINTEY NOTES. 1970. 1 1970-1474 A 2004007

2002. SOMECHINE MANNY 1174-04012

2002. SOMECHINE MANNY 1174-040

JJS COSTRIGHT 2008 ACS on STR 2007:1115254 CAPLUS 147:427340 Beninidatelyl-pyridine compounds for inflammati

INVENTOR(S): PATENT ASSIGNAL(S): SOURCE:

DOCUMENT TYPE: LANGUAGE: FAMILY ACC. NUM. COUNT: PATENT INFORMATION:

DATE

PRIORITY APRIL TOPO P 20040323

MAD DAY 142-422240

The investion relates to coepds. of formula I or a pharmaceutically acceptable salt, solvate, clathrate, or prodrug thereof. Coepds. of formula I wherein YZ is [univestituted alken]. [univestituted alken]

ARSMER 3 OF 20 CAPLUS COPYRIGHT 2008 ACS on STN [Continued]

THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE

AMEMER 4 OF 20 CAPLUS COPYRIGHT 2008 ACS on STM (Continued) (um)substituted cycloalkyl, (um)substituted aryl, etc., each 2 is independently (um)substituted alkyl, (un)substituted alkenyl, (um)substituted alkynyl, (um)substituted cycloalkyl, halo, CN, etc., L1

aminoalkyl, CO, NHCO and derivs., CONH and derivs., CCO, CCO, etc.; R9

delication, on most offerent and the second of the second

es) (drug candidate; preparation of benzimudazolylpyzidine compds. useful

immunoruppressive agents or in treatment and prevention of inflammatory, immune and allergic disorders)

Markov Company

Benanator Company

Benanator Company

Benanator Company

Reference Company

Refere

BSOlve-Ja-- Benzamide, [5-(a,l-dimethylethyl)-2-(trafiu --\nh-mul]-2,3-difluoro- (CA 1)-18-benzinidazol-ICA THERE HAME!

880176-39-6 CAPLUS Benzanide, N-[4-[5,6-dimethyl-2-(trifleoromethyl)-1H-benzinidazol-1-yl]phenyl-2,3-difleoro- (CA INDEX NOME)

ARISMEN 4 OF 20 CAPLUS COPYRIGHT 2008 ACS on STR

21 880176-59-0 CAPLUS
22 Destraintée,
-{4-(2,3-buigftsfluoromethyl)-18-bensinidazol-1-yl]phemyl]-2,3difluoro- (CA INEEK NAME)

880176-91-0 CANUS 12-bearindsrole-5-ourbowylic actd, 1-(4-(42,7-difluorobenroyl)anino]phenyl)-2-(trifluoromethyl)-, methyl ester (GA INEXX NEX)

$$\operatorname{Ner} = \bigcup_{i=1}^{n} \operatorname{Ner} = \bigcup_{i=1}^{n} \operatorname{Ner}$$

PER 080177-08-2 CAPLUS CN 18-ReszInidazole-5-carboxanide, 1-[4-[12,3-difluorobenzoyl)amino]phenyl]-2-[Exifluorobethyl)- [CA INDEX NAME)

NY 680177-28-6 CAPLUS CM Benranide, N-[4-[5-acesyl-2-(txifluoxomethyl)-18-benrinidarol-1-yl]phenyl) 2,3-difluoro- (CA NUBER NAME)

NUIS CONTRIBET 2008 ACS on ETH
2007:108742 CMPLUS
1471:0634801/pyratime compounds for inflamenti
and premome-related uses and their preparation
Chem, Shoryum Janes, June Janes, Juny Janes,
Synta Pharmaceultain Comp., COM.
OCOMER 120000 16389
Netest

PATENT	200.			KIN	D	DATE			APPL	ICAT	ioes :	90.		D	ATE	
WO 200	71093	62		3.2			0927		WO 2		0872	96		- 2	0070	320
M+	AE,	NO.	22.	225	27.	207.	22.	Bh.	BB.	вз.	BB.	BR.	BM.	BY.	BZ.	Ch,
	CE.	CN.	00,	CR.	CU.	CZ,	DE.	DK.	Det.	DE.	EC.	EE.	EG.	ES.	FI.	GB,
	an,	GE,	CB.	CM.	97.	Het.	88.	87,	ID.	22.	228.	18.	JP.	KE,	203.	221,
	222.	XP.	200.	EZ.	1.5.	LC.	LK.	LR.	1.5.	LT.	LU.	LY.	MA.	MD.	MG.	MX.
	202.	207.	NO.	MY.	MZ.	30%	397.	MI.	390.	NEE.	CM.	PG.	PH.	Pl.	PT.	70.
	22.	BU.	ac.	SD.	SE.	22.	SX.	51.	504.	sv.	SY.	TJ.	TN.	TH.	TR.	77.
	TZ.	UA.	DG.	US.	UZ.	WC.	1777	23.	224.	234						
300	87.	BE.	33,	CE,	CY.	CZ,	DE.	DK.	EE,	ES,	FI.	FR.	Œ,	as,	BU,	IE,
	18,	27.	1.7.	1,07,	1.77	MC.	MT.	NL.	P2.,	PT.	BO.	SE,	81.	8%,	78.	BF.
	BJ.	CF.	C3,	CI.	CH.	on.	cet.	00,	ON.	ML	MR.	NE.	827.	TD.	TG.	BM.
	OB,	CM.	XE.	1.8.	NW.	ME.	100.	SD,	83.,	82.	TE.	DO.	221,	251,	221,	25.
	BY.	203.	XZ.	MD.	207.	TJ.	TM									
US 200	10249	609		8.2		2007	1025		CS 2	007-	7260	72		- 2	0070	320
PRICRITY AP	P122.	mro							US 2	-300	7840	37P		P 2	0060	320

OTHER SOURCE(S): MARRAT 147:406840

$$(y_2)^{1/2} \xrightarrow{y_2} y_2^{-1} \xrightarrow{y_1} z_1$$

The invention relates to compds of structural formula I or a pharmacertically acceptable salt, solvate, dathste, or prodrug thereof. Compds. of formula I wherein XI, XZ, and XI are independently CB, CR and NY b is a libber; Y is indisplayable three displays, insubstituted alkeys, may be a latery in the composite of the composite content of the product of the composite content of the product of the composite of the content of the composite of the content of the conten

IS COPYRIGHT 2008 ACS on STN

AMMENT OF 30 CAMPAN CONTROL TORS AT ON THE CONTRACTOR OF STREET, AND ASSESSMENT OF THE CONTRACTOR OF STREET, AND ASSESSMENT OF THE CONTRACTOR OF THE CONTRAC

950844-60-1P 950844-69-2P 950844-50-3P 950844-50-3P 950844-51-4P 950844-52-7P 950844-53-3P 950844-51-4P 950844-51-4P 950844-51-4P 950844-51-4P 950844-51-4P 950844-51-4P 950844-71-4P 950844-71-4P 950844-71-4P 950844-71-4P 950844-71-4P 950844-71-4P 950844-71-4P 950844-71-4P 950844-71-4P 950844-61-2P 95084

(Pharmacological activity); SPN (Synthetic preparation); THU watic use); BIGL (Biological study); PREP (Preparation); USES

drug candidate; preparation of benzinidazolylpyrazine compds: useful treatment and prevention of inflammatory, allergic and innune

M665)
950844-48-1 CARLOS
IN-Benrinidarole-5-carboxylic acid,
115-Enrinidarole-5-carboxylic acid,
1-[5-[[0.5-diffboro-4-pyridimyl)carboxyl]anino]-2-pyrazinyl]-2(trifisorosethyl)-, methyl exter (CA INDEX MOME)

18 AMENES 5 OF 20 CAPLUS COPYRIGHT 2008 ACS on STR (Continued

30 35844-42-2 CAPAS 10 18-Ennamidarole-5-carboxylic scid, 1-(5-[(15-fluoro-6-pyradiny)]carboxyl]amino]-2-pyrazinyl]-1-(5-[(10-fluoro-bul) - arms (72 1999 Mary)

732 950844-50-5 CAPLUS
CM 1E-Tempinidascie-5-carboxylic acid,
1-[5-[(3-methyl-4-pyridinyl)carboxyl]anino]-2-pyrazinyl]-2[trifluocomethyl)-, nethyl ester (CA INDEX NAME)

329 950444-51-6 CAPUNS
01 18-Pear indisorde-5-carboxylio acid,
1-[5-[(2-floorobentoyllanino]-2-pyrazinyl]-2-[triflooromethyl)-, methyl
ester (CA INDEX NAME)

18 ANSWER 5 OF 20 CAPLUS COPYRIGHT 2008 ACS on STR (Continued)

329 30044-53-0 CARUM CONTINUED TO THE PROPERTY OF THE PRO

R1 950844-57-2 CAPLUS
CR 1E-Sentimidatole-5-carboxylic and,
1-[5-[(12-sent)y1-3-pyridiny1)carboxyllanino]-2-pyraziny1]-2[trifiuorosethyl)-, nethyl eater (CA INDEX NAME)

LO AMSMER 5 OF 20 CAPLUS COPYRIGHT 2000 ACS on STN (Continued)

RN 950644-52-7 CAPLES
CN 18-Benrimidarole-5-carboxylic acid,
1-[5-[12,5-dathworobenroyl)amamo]-2-pyrazamyl]-2-[trafluoromethyl)-,

38 950844-53-8 CAPLUS CB 1Hs Bern inidistone-f-carboxylic acid, 1-[5-[42,4-difluorobenroyl)amino]-2-pyrarinyl]-2-[trifluoromethyl)-, methyl ester (CA INDEX NUME)

38 950844-54-9 CAPLUS CB 1H-Bentinidazole-5-carboxylio acid, 1-[5-[42-3,6-trifluorobenzoyl)amino]-2-pyrazinyl]-2-(trifluoromethyl)-, methyl erier (CA INDEX NUME).

LO ANSMER 5 OF 20 CAPLUS COPYRIGHT 2000 ACS on STN (Continues)

380 300844-56-3 CAPLOS ON IR-Bentinidacole-Scarboxylic acid, 1-[5-[[(4-methyl-1,2,2-thiadiarol-3-yl)carboxyl]amino]-2-pyraxxnyl]-2-(trifluoroesetyl)-, methyl ester (CA INDEX NOME)

RN 950844-71-0 CAPLUS CN 18-Benzimidazole-5-carboxylic acid,

1-|5-|[(2,6-difluorophenyl)nethyl]amino]-2-pyrazinyl]-2-(trifluoromethyl)-, nethyl ester (Ch INDEX NAME)

HN 950844-72-1 CAPLES

(N 18-Benzimidazole-5-carbonylic acid,
1-[5-1[3,5-difiboro-4-pyridinyl)methyl]amino]-2-pyrazinyl]-2(trifiboromethyl)-, methyl exter (CA INDEX NUME)

18 ANSWER 5 OF 20 CAPLUS COPYRIGHT 2008 ACS on STR (Continued)

PM 950844-71-2 CAPARS
CM 1R-Remaindarole-5-carbonylic acid,
1-(5-[(3-fluoro-bypxidimyl)methyl)amino)-2-pyxazimyl)-2[trifluoroesthyl)-, methyl ester (CA INDEX NAME)

22 9:0044-74-3 CAPLUS CN 1E-Renrinidarole-5-carboxylic acid, 1-(5-(((3-methy)2-(-pyridimy1)methy1)anino)-2-pyrariny1)-2trifluoromethy1)-, nethy1 ester (CA INDEX NAME)

22 350844-73-4 CAPLUS
2 1E-Bentunidatole-1-carboxylic acid,
1-{5-{[(2-fixoropharyl)nethy2]anino}-2-pyrarinyl}-2-(trifluoroesethyl)-,
nethyl star [(A. INDEX NAME)

921 950844-76-5 CAPLUS

18 ANSWER 5 OF 20 CAPLUS COPYRIGHT 2008 ACS on STR (Continued)

230 30044-80-1 CARLOS
13-Beaumidatole-5-carboxyllo acid,
1-[5-[([2-methylphenyl]methyl]anino]-2-pyrazinyl]-2-(trifluoromethyl)-,
methyl ester (CA INDEX NAME)

PM 950844-81-2 CAPLUS
CN IR-Benrandarole-5-carboxylic acid,
1-(5-[(12-nethyl-2-pyridinyl)nethyl)anino]-2-pyrazinyl)-2[trafluoromethyl)-, nethyl exter (CA INDEX NDMS)

30 350-4-a-2-) CAUGOS 18-Fearmaindasa0-F-oarbeay2as aoud, 1-(6-[(4-net-byl-2-2-2-th)adiazol-5-yl)nethyl)amino]-2-pyrazinyl)-2-(rifibacomethyl)-, methyl aeter (CA INDEX MOME) L8 AMEMER 5 OF 20 CAPLUS COPYRIGHT 2008 ACS on STN (Continued) CN 18-Benzimidazole-5-carboxylic acid,

1-[5-[[(2,5-difluorophenyl)methyl]amino]-2-pyrazinyl]-2-(trifluoromethyl)-, methyl exter (CA INDEX NAME)

NN 950844-77-6 CAPLUS CN 18-Benzinidarole-5-carboxylic scid,

1-[5-[[(2,6-difluorophenyl)methyl]amino]-2-pyrazinyl]-2-[trifluoromethyl)-, methyl exter (CA INDEX NAME)

28 35084-78-7 CARUS 1B.Bennindianole-5-carboxylic acid, 2-(trifluoromethyl)-1-[5-[[12,7,6-trifluoromethyl]amino]-2pyxasimyl-, methyl ester (CA INGES NAME)

NN 950844-79-8 CAPLOS
CN 10-Benzinidazole-5-carboxylio acid,
1-[5-1[(4-chloro-2-Cluorophenyl)methyl]animo]-2-pyrazznyl]-2(txiCluoromethyl)-, methyl ester (CA INDEX NOME)

LO ANSWER 5 OF 20 CAPLUS COPYRIGHT 2000 ACS on STN (Continued)

930846-03-69 930846-06-79 930846-07-8P Ris RCT (Reactant); REM (Synthetic preparation); FREM (Preparation); FRC (Reactant or reagent) (Intermediate; preparation of benzamidatoly); pyrazine occepts, useful in treatment and prevention of inflammatory, allergic and immune

.seases)
950846-05-6 CARUS
18-Benrinidarole-5-carboxylic acid,
18-Benrinidarole-5-carboxylic acid,
1-(5-brone-2-pyrasinyl)-2-(trifluoromethyl)-, methyl ester (CA INDEX

No. 1B-Denninidarole-5-carboxylic acid, 1-[5-[12,6-dafflworobenroyl)animo]-2-pyrarinyl]-2-(triflworomethyl)- (CA NUMEN NOME)

20 950846-07-8 CAPLES
21 115-Emministrole-5-carboxamide, N-(2,2-diethoxyethy1)-1=|5-[(2,6-difisorobemoyl)anno]-2-pyramy1]-2-(trifisorobethy1)- (CA INDEX NAME)

ASSMER 5 OF 20 CAPLUS COPYRIGHT 2008 ACS on STR

ARRIVER 6 OF 20 CAPLUS COPYRIGHT 2008 ACS on STR Variania B12 (CA INDEX NAME)

PAGE 1-A

PAGE 2-A

L8 AMEMER 6 OF 20 ACCESSION NUMBER:

DOCUMENT NUMBER:

167:152831
Transdermal delivery of pharmaceutical agent comprising genetic molecule comprising communication of the comprising communication of the communic PATERT ACCTOMENTS.

DOCUMENT TYPE: LANGUAGE: FAMILY ACC. NUM. COUNT: PATENT INFORMATION:

APPLICATION NO AU 2006-905107

MO 2006-AU1999 The present invention generally relates to a vehicle useful for delivering
a pharmaceutically active compound including a genetic mol. or

d phinacomically weare one-saltion More particularly, the present invention provides microemulsions for transformal delivery of pharmacomically active agents to a subject. Thus, stable microemulsion was formed by mixing 16 g of oil (Crodunol

The state of the s

NOMES 6 OF 30 CASUMS COTTAINED 2009 ACS on THE COMCOMMANNA, AUGUSTA 13425-354, Papersoncealisms. AUGUSTA
13425-344, Papersoncealisms 1379-35-35,
13425-344, Papersoncealisms 1379-35-35, Communications 13425-344, Papersoncealisms 13425-344, Papersonceali

PAGE 1-A

PAGE 1-A

- 13115-03-2 CAPLUS Vitamin B12-57Co (CA INDEX NAME)
- STRUCTURE DIAGRAM IS NOT AVAILABLE ***
 13408-78-1 CAPLIS
 Obblannie, dibydrogen phosphate (ester), inner salt, 3'-ester with
 (5;6-dimenthyl-1-e-b-riked granosyl-18-bennimidarole-will),
 colls) [SI] (CA 18028 MM25)

PAGE 1-A

PAGE 1-A

13422-52-1 CAPLUS Cobinamide, Co-aqua-, dihydrogen phosphate (ester), inner salt, 3'-ester

18 MRSMER 6 OF 20 CAPLUS COPTRIGHT 2008 ACS on STH (Continued) with (5,6-dimethyl=1-a-D-ribofranosyl-18-benzimidazole-wR3), [cont.] (1,1 [cont.]) (72 may 2007 [cont.])

PAGE 1-A

LS AMEMBER 6 OF 20 CAPLUS COPYRIGHT 2008 ACS on STN (Continues PAGE 3-A

RN 13422-53-2 CAPLUS CN Vitamin B12-40Co (CA INDEX NAME)

*** STRUCTURE DIMONAM IS NOT AVAILABLE ***
RM 13422-55-4 CAPLUS
CN Cobinamide, Co-methyl-, dihydrogen phosphate (ester), inner

PACE 3-A



N 1870-90-1 CMPUTS
Cobinande, Co-[5-decoyaderosin-5-7]-, f-(dhydrogen phosphate), inner mail, 3'-derter with [5,4-dinethyl-1-a-0-ribofuranosyl-18-benzinidarole-MU] [9CI] (CA INDEX NUME)

PAGE 1-A

PAGE 3-A

RN 14978-39-3 CAPUNS
CO Cobinamide, Co-(thiocyanato-wS)-, dihydrogen phosphate (ester nimer salt, 3'-ester with (5,6-dimethyl-1-w-0-ribofuranosyl-1

PAGE 1-A

PAGE 1-A

PAGE 2-A

RN 15041-07-3 CAPL/S CN Cobinande, Co-chloro-, dihydrogen phosphate (ester), immer salt, 3'-ester With (5.6-dimethyl-1-w-D-ribofuranosyl-18-benzimidazole-wN3)

PAGE 1-A

PAGE 2-A

15671-27-9 CAPLUS Colstannide, Co-(sulfito-wO)-, dihydrogen phosphate (ester), inner

NOCTURE DIAGRAM IS NOT AWAILABLE ***
0623-1-6 CANEUS
06123-1-6 CANEUS
06123-1-6 CANEUS
06123-1-6 CANEUS
06123-1-6 CANEUS
11, 37-aster with (5,6-dimethyl-1-a-0-ribofurancsyl-1Renindiazolo-2031) (CA IROK NOME)

PAGE 2-A

38 34502-77-7 CAPUES CB Communite, Co-[3-(6-anino-98-purin-9-y1)propy1)-, dihydrogen phozphate [exter], inner salt, 3*-exter with [5-(6-dimethyl-1-e-0-riboturanoxyl-18-benrinidarole-x83) | CA

PACE 1-A

18 ARENES 6 OF 20 CAPLUS COPYRIGHT 2008 ACS on STR (Continued)

LB ANSWER G OF 20 CAPLUS COPYRIGHT 2008 ACS on STN (Continued PAGE 2-8

38 41632-95-5 CAPLUS ON Hydrogenobinamide, dihydrogen phosphate (exter), 3"-exter with 5,6-dimethyl-1-a-D-ribofuranosyl-18-benzimidazole (CA INDEX NAME)

PAGE 1-8

- 18 AMENIER 6 OF 20 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
- 55565-91-8 CAPLIE Vitamim E12-56Co (CA INDEX NAME)
- TRECTURE BLAGRAM IS NOT AVAILABLE ***

 MINN-23-4 COMPUS

 Gobinanade, On-[-(-anino-98-puris-2-yl)pantyl]-, dihydrogen phosphate
 leater), inner salt, 37-ester with

 [5-dimethyl-i-o-0-xinodrusonyl-in-benzinidazole-sdf) (CA

PAGE 1-A

PAGE 1-A

59269-78-8 CAPLUS
Cobinantide, Co-[2-(6-anino-98-purin-9-y1)ethyl]-, dihydrogen phorphate
(exter), inner sait, 3'-ester with
(5, 6-dimethyl-1-e-0-ribofurnsoryl-18-benrinidazole-sk3) (CA

PAGE 1-A

ANSWER 6 OF 20 CAPLUS COPYRIGHT 2008 ACS on STH

REFERENCE COUNT: THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CUTATIONS AVAILABLE IN THE RE

Li AMBREA 7 of 20 CADUAR COMPANIENT COMP AND ON STEEL ACCORDANCE AND ADMINISTRATION OF THE ACCORDANCE AND ADMINISTRATION O

DOCUMENT TYPE: LANGUAGE: FAMILY ACC: NUM. COUNT:

PATERT NO. APPLICATION NO.

| Martin | 100 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 2

MO 2006-AU1965 M 20061221

OTHER DOUGHEST AMERICAN AND ATTACHMENT OF SPECIAL PROPERTY OF THE AND ADDRESS AND ADDRESS

94263-74-75

La JEZ (Branamological activity) FEF (Droperlias) STR (Dynhetic La JEZ (Branamological activity) FEF (Droperlias) STR (Dynhetic Droperlias) STR (Stranamological activity) FEE (Branamological Stranamological Branamological Branamologi

AMEMIA 7 OF 20 CAPLUS COPYRIGHT 2009 ACS on STR [MIT imbibitors] 92609-75-8 CAPLUS 28-Senishidarol-2-ome, 1,3-dihydro-5-[2-[[2-hydrox] [CA INCLE NUMB]

me, 1,3-dihydro-5-[2-[(2-hydroxyethy1)thio]acety1]-

942603-78-1 CAPLUS 28-Beninnidarol-2-ore, 1,3-dihydro-5-[2-[(6-hydrosybesyl)thio]acetyl] [CA INDEX NAME)

942609-90-7 CAPLUS 2E-Benzamidarol-2-one, 5-[2-(betylthio)acetyl]-6-chloro-1,3-dihydro-

942408-92-9 CAPUUS 28-Bensunidazol-2-one, 5-[2-(betylthio)acetyl]-1,2-dibydro-1,3-dinethyl-[CA IBBUS RAME]

LB ANSMER 7 OF 20 CAPLUS COPYRIGHT 2008 ACS on STN [Continued]

94269-72-4F 94369-72-5F 942499-73-6F
BLE DNC (Dharmacological activity) NCT (Deactant) 2HH (Symbolic propagation) 750 (Therapeut cone) 12HL (Boliopeut athor) 12

942609-72-5 CAPLUS
Propanoic acid, 3-[[2-(2,3-dihydro-2-oxo-1E-benzimidazo1-5-yl)-2-oxo-thylithio]- (CA INDEX NAME)

942409-73-6 CAPLUS Acetic acid, 2-[[2-12,3-dibydro-2-oxo-18-bentimidarol-5-yl)-2-oxocthyllthiol. methyl ester (CA INDEX NAME)

94209-75-87 94209-76-17 94209-90-79 94209-79-79 94209-79-79 94209-79-70 94209-94-17 94209-96-92 Ri PRC (Pharmacolgical activity) SPN (Synthetic preparation); 780 (Therapeutic use); NICA (Biological study); PERF (Preparation); USE

ANSMER 7 OF 20 CAPLUS COPYRIGHT 2008 ACS on STN

942609-93-0 CAPLOS Propancie acid, [[2-[6-chloro-2, 3-dihydro-2-oxo-18-benzimidazol-5-yl)-2-oxocthyl]thio]- (CA INDEX NUME)

5-[2-(butylthio)acetyl]-6-chloro-1,3-dihydro-1,3dazol-2-one, 5-| (CA INDEX NAME)

942499-95-2 CMPAUS Propanoic acid, 3-[[2-(6-chloro-2,3-dihydro-1,3-dimethyl-2-oxo-1E-beninidarol-5-yl)-2-oxoethyl]thio| (CA INDEX NAME)

9305.4.4.8 9302.51-89 897545-61-89 87945-63-69 El: EXT [Beatlant]; SBM [Synthetic preparation]; PREP [Preparation]; PACT [Desciant or reagent) 9302-0.1-4 CANUS 23-6-en:indisatol-c-one, b-(2-chloreacety)]-1,7-dibjeto- (CA INSEK SOME)

AMBMER 7 OF 20 CAPLUS COPYRIGHT 2008 ACS on STR

2E-Benzinidarol-2-ore, 5-chloro-6-(2-chloroacetyl)-1,3-dihydro- (CA

ver.u--es-e CARLUS 2E-Benrumdard-2-one, 5-chloro-6-(2-chloroacetyl)-1,3-dihydro-1,3-dimethyl- (CA INDEX NAME)

THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE

AMENER 8 OF 20 CAPLUS CONTRIGHT 2008 ACS on STR

- q, a = independently 0-6; R9 = H, (un)substituted alk(en/yn)yl, etc.; G0 N. O. H. Cér if 00 = N. then cach EJ. Né = independently N. CTJ. F. Cl. Ex. I. Cot. Obc. Cd. CCTJ. NEJ. tru substituted hydroxy/aumon/alkyl-Colland-CCCClland-CCCClland-CCClland-CCClland-CCClland-CCCClland-CCClland-CCClland-CCCClland-C

- 78. I are useful for treating various angiogenic and hematol. association disorders, such as myeloproliferative disorder in patients who do not respond to kinase-inhibition therapy that comprises administering approved.
- oven
 medications Ine data).
 9370[3-29-28 9370]3-22-49,
 7-(18)-2-[2-[4-[Piperidin-4-yl)sulfonyl]phenyl]anino]pyrinidin-5yl]ethenyl]-5-(triflooremethyl)-18-benninidarol-2-anine

L8 AMEMER 8 OF 20 ACCESSION NUMBER:

JE COPYRIGHT 2008 ACS on STR 2007:538389 CAPLUS 146:521831

convision CALLOS

reportation of as membered beterostronalis,
particularly pyramidism and triansam, shibitors
particularly pyramidism and triansam, shibitors
particularly pyramidism and triansam, shibitors
(as, Jianger) shoot, John Lings, Bang Mai, Anderson,
(as, Jianger) shoot, John Lings, Bang Mai, Anderson,
(as, Jianger) shibitor, Johnson, John Mai, Anderson,
(as, Johnson, Johnson, Johnson, Johnson,
(as, Johnson, Johnson, Johnson, Johnson, Johnson, Johnson, Johnson,
(as, Johnson, Johns

PATENT ASSIGNEE(S):

DOCUMENT TYPE: LANGUAGE: PAMILY ACC: NUM. CO PATENT INFORMATION:

	15511				KIN		INTE			APPL	ICAT					NTE	
WO	2007	0560	75		A2		2007	0518		MO 2	00E-	0542	0.20			0061	031
900	2007				A3			0920									
	961	AE,	NG,	AL,	AN,	AT,	AU,	AZ,	RA,	BB,	BG,	BR.	29%	BY,	RZ,	Ch,	CH,
		CN.	00,	CE,	CU,	CT,	DE.	DE.	DN.	DE.	EC.	EE,	EG.	ES.	FI.	GB.	GD.
		CE,	GB.	CN.	GT.	HN.	BEL	BU.	ID,	IL	339,	18,	JP.	KE,	EG.	ES.	KN.
		KP.	KE,	EZ.	Lhe	LC.	LE.	LEG	LS.	LT	LU.	LV.	LY	NA	ND.	MO.	MK.
		MN.	MW.	NO.	NO.	No.	104	200,	NI.	290	No.	CNG	PG,	PH.	PL.	PT.	BO
		RG.	BU.	ac.	SID.	SE.	50.	SE.	SIL	SN.	SW.	SY.	TJ.	TN.	TN.	TR.	TT.
		TI,	UA,	DG,	US,	UZ,	VC,	WN,	23,	224,	236						
	3561	AT,	RE,	BG,	CE,	CY,	CZ,	DE,	DE,	EE,	ES,	FI,	FR,	GB,	GR,	NU.	IE,
		IS,	IT,	LT,	LU,	LV,	NC,	NL,	PL,	PT,	DO,	SE,	SI,	SE,	TR,	BF,	BJ,
		CF.	co,	CI.	CN,	Oh,	CRN,	90,	OW,	NL.	NB,	NE.	SN.	TD.	TG.	BW.	QH.
		CN.	KE,	LS.	Mil.	NZ,	100.	SD,	SL,	85,	TI.	03,	226	SW.	AN.	AS.	BY.
		EG,	EZ,	MD,	BU.	TJ.	TN.	AP.	EA.	EP.	OA						
US	2007	0149	598		A1			9628		US 2	006-	5910	76			0061	
US	2007	0161	645		A1		2007	0712		05 2	-300	5912	52		2	0061	031
ORITE	ADD	130	TRITO										15P				

OTHER SOURCE(S): MARPAT 146:521831

ASSESS 50 20 CAUSE CONFIDENT 500 ACT on FM. (Contacted) 97913-35-79, [Climberled plants of the property of the

(Theispectic use;) such uniocolosis stopy;) was Preparation); uses (drug candidate; preps. of six membered betwearces, particularly principles and triarise, inhibitors targeting resistant kinase matalions. 2002. 2007. [Inc. 2-(IR)-benezimidatoi-6-ya)athenyl]-N-[4-(4-physicialysis)athory)phemyl]- (CA NEOEX NORT)

937013-22-4 CAPLUS
1B-Benrinidarol-2-anine, 7-[(1E)-2-[2-[[4-(4-piperadisplaulfonyl)phenyl]anino]-5-pyrinidinyl]ethenyl]-5-(trifluoromethyl)- (CA_INDEX_WME)

Double bond geometry as shown

RN 937013-25-7 CAPLUS

MRMER, 8 OF 20 CAPLUS COPYRIGHT 2008 MCS on STM (Continued) 2-Dytinidinanine, N=(4-(4-ptperidinylsulforyl)pheryl)-5=(1E)-2=(5-(1E)-2-(1E)-2-(5-(1E)-2-(5-(1E)-2-(5-(1E)-2-(1E)-2-(5-(1E)-2-(1E)-2-(1E)-2-(1E)-2-(1E)-2-(1E)-2-(1E)

ble bond geometry as shown.

DE 937014-92-1 CAPUMS
CH 1R-Bess midssol-2-mine, 6-[(1E)-2-[2-[[4-(4-g)peridnylselfcoyl)phenyl]snino]-5-pyrinidnylethenyl]- (CA DEBEX NAME)

Double bond geometry as shown.

257013-69-5 CAPLUS Methamesifecia end, 1,1,1-trifluoro-, compd. with 5-(1E)-2-(1E-benzimidizol-6-yl)ethemyl)-8-[4-(4-piperidinyleufcowl))benyl)-2-pyrindisamine (1+7) (CA INDEX NAME)

CMS 937013-20-2 CMF C24 H24 NO C2 S

Double bond geometry as shown.

DOCUMENT TYPE: LANGUAGE: FAMILY ACC. NUM. COUNT:

	LISSI						DATE				ICAT					ATE	
Mo	2007	0358	43		3.2		2007	0329			006-					0060	
	W1	CN, GE, KR, NW, RU, RU, NA, AT, IS, CF,	CO, GE, KE, SC, SC, UG, BE, 17, CG,	CN, GM, LA, NT, SD, US, BG, LT, C1,	CU, IN, IC, MZ, SE, UZ, CH, CM,	CE, IX, IX, SG, VC, CY, CY,	DE, HD, LR, NG, SK, VN, CE, MC, GN,	DK, ID, IS, SI, SA, DE, NL,	IM, II, NO, SM, SM, DK, PL, GM,	DE, IN, LU, SV, SW, EE, ML,	BG, EC, IS, IV, GM, SY, ES, RO, MR, TE,	EE, JP, LY, PG, TJ, FI, SE, NE,	EG, KE, NA, PH, TM, FR, SI, SN,	ES, MG, MD, PL, TN, GB, SK, TD,	PI, NG, NG, PT, TR, TR,	GB, MK, NK, RO, TT, BP, BM,	GD, KP, MN, RS, TZ, TZ, BJ, GH,
US	2006 2007 2008 7 APP	X5, 2922 0128 0754	XZ, 03 174 94	NED,	AL AL	IJ,	TM, 2007 2007	AP, 0329 0507	EA,	MD 2 MB 2 MB 2 MB 2 MB 2	OA -	2922 5262 7095 7197 U835	03 02 66 43P 676		2 2 2 2 2 2 2 3 4	0080 0080 0080	921 921 421 921 914

- Materials and methods for treating times offered as home or small times among unjournable office as home offered as home or small times among unjournable office as described. Further, outlier out of subjects were offered to the size defects any part transfer of the size offered and part transfer or see solls are also described, which are part to transfer or see solls are also described that the size offered as the size of the size offered as the size of the size offered as the size of the size

LO ANSMER 0 OF 20 CAPLUS COPYRIGHT 2000 ACS on STN (Continued)

LO ANSMER 9 OF 20 CAPLUS COPYRIGHT 2000 ACS on STN

PAGE 1-A

$${\rm H_2N-\overset{\circ}{C}-CH_2-CH_2} \quad \ \ \, {\rm Me} \quad \ \ \, {\rm Me} \quad \ \, {\rm CH_2-\overset{\circ}{C}-MH_2} \quad \ \, {\rm Me}$$

MUS COPTRIGHT 2008 ACS on STN 2006:982167 CAPLUS 145:348597 18 AMENUS 10 OF 20 CAPLUS ACCESSION NUMBER: 200

18539397

We of phemylmethinazoles, methinazole derivatives, and tastomeric cyclic thioses for the treatment of actioners/sinchesstop diseased azocated with Noble, keeping of the property of the Company of the Contact of the Chipman of the Chipma

PATERT ASSIGNACES

USA. U.S. Pat. Appl. Publ., 102 pp., Cont.-an-part of U.S. Ser. No. 912,948. CONDEN. UNDOCO Patent

OCUMENT TIPE; ANGUAGE; AMILY ACC. BUM. COUNT;

	1227				XIN		DATE				ICAT					A7E	
	2006	0211			- 23		2006			DG :	2005-	1303			- 2	0050	
	2005				2.3						2004-						316
MZ.	2004	3179	93		- 81					MI S	0004-	3179	93		- 2	0040	316
CA.	2559	712			- 20			1013		CA :	0004-	2559			- 2	0040	316
EF	1725	230			- 2.1			1129		EP :	0004-	8218	36		- 2	0040	316
	201	ATV	BE.	80,	CB,	CY.	CE,	DE.	DK.	EE,	25,	FI.	PE.	CB,	CE.	BU.	IE
		17.	LIL	1.07	MC.	NL.	PL	PT.	BO.	SE	SIL	SK.	TR				
JP.	2003	5295	10		7					JP :	2007-	5038	62		23	0040	
OS.	2006	0050	36.5		83					05 3	2004-	2122	40		- 2	0040	300
AU.	2006	2475	0.4		3.3					AU S	2006-	2475	0.4		- 2		
CX	2606	76.9			3.1					CA :	1006-		76.9		2	0060	
MO.	2006	1246	76		- 81		2006			WO 3	-9006	0818	55.4		- 2	00.60	
	56 1	AE,	200,	Alice	225	AT.	NO.	AZ.	804	BB.	BO.	BE.	256.	BY.	BE.	Ch,	CB.
		CSI.	00,	CS.	CU,	CE,	DE.	DK.	Det.	DZ.	EC.	EE,	EG.	ES.	PI.	CB,	CD
		GE.	GE.	C84.	100.4	HU.	ID.	IL	IN.	15.	JP.	KE,	2007	220	201.	KP.	KE
		XX.	LC	LK.	LR	LS.	LT	LU	LW	LY	MA	MD.	MG.	NO.	MIL.	MN.	NO
		MZ.	333.	3907	NI.	300.	NT.	CM	PG.	PH.	PL	PT.	DO.	BU.	pc.	SD.	SE

00, 58 c. 83, 58 c. 77, 72, 78 c. 78, 78 c. 77, 77, 78 c. 80, 50, 50 c. 82 c. 82 c. 83 c.

DR 2004-912948 MO 2004-057888 A 20040316

MO 2006-0818554 M 20060511

OTHER SOURCE(S): MARPAT 145+348597

AMENER 10 OF 20 CAPLUS COPYRIGHT 2008 ACS on STN

PAGE 1-A

tor 3
[TLEI] as well as Toll-like receptor 4 (TLE4) and/or TLEI/TLEA signali in nonsmune cells, monocytes, macrophages, and/or dendritic sells in association with related pathologies. This immention also relates to

ase
of phenylmethinazoles, methinazole derivs., and tautomeric cyclic thioner
for the treatment of autoimmume and inflammatory diseases associated with
Toll-like receptor 3 [TMRS] as well as Toll-like receptor 4 [TMRS] and
TMRS/TMR signaling in monimume calls, mesocytes, macrophages, and/or
demotrize calls in association with called pubblogues. This invention

relater to treating a subject having a disease or condition associated shearent Pull-lik receptor I as well as Tull-like receptor 4 am/or TLAVIII separating in monimose cells, mesory-as assergates, and control exist in assergation with related pathologies. The present pathologies of themselves of the provided and the pathologies of the pathologies and chemolites on typicalse moduted diseases associated and the pathologies and the pathologies and diseases associated pharmacetteni formations capable of thabiting the ITP-3/Type I INTERNATIZEATIZEATIZE pathony associated with Tull-like tempora

| INDIVIDUAL CONTROL OF THE PROPERTY OF STATES OF STATES

tautomeric cyclic thiomer for treatment of autoimmume/inflammatory diseases associated with toll-like receptor overexpression) 06-19-9 CATAUMS Vitamin BIZ CA INDEX NAME)

CARLING CONTRIBUTE 2009 ACC on THE 2004-085725 CARLING THE ACCURATE TO THE ACCURATE ACCURATE

PATENT ASSIGNEE(S):

DOCUMENT TYPE: LANGUAGE: FAMILY ACC. NUM. COUNT: PATENT INFORMATION:

	TEST										LICAT						
WO	2006										2006-						
	W:										, BG,						
											DC,						
		GE,	GE,	CN,	HE,	HU,	ID,	IL,	IN,	IS.	JP,	XE,	293,	224,	200,	MP,	XX
		KZ,	LC,	LK,	LE,	LS,	LT,	LU,	LV,	LY	NO.,	MD,	MG,	MX,	NO.	356,	300
		ME.	No.	N3,	NI.	NO,	NE.	CN,	PG,	PR	PL.	PT.	BO,	BU.	80,	SD,	SE
		83,	8K,	8L,	SM,	87,	TJ.	TH.	TN,	TR	TT.	TE.	00%	03,	08,	UZ.	vc
		VN.	YU.	23.	224,	SM											
	XM:	NT.	BE.	BG.	CB,	CY,	CE,	DE.	DK.	EE	E8.	FI.	PB.	GB,	GB.	BU.	IE
		15.	IT.	LT.	LU.	LV.	MC.	ML	PL.	FI	DO.	SE.	SI.	58.	TR.	BF.	5.7
		Cr.	og,	CI.	CN	GA,	CSI.	go,	GM.	ML	MR.	ME.	500	TD.	TG.	me.	GH
		GN.	KE,	LS.	MM.	NZ.	30%	SD.	SL.	52	TZ.	OG.	22%	276	200	AZ.	BY
		103.	KZ.	MD.	BU.	TJ.	771										
ACI	2006	21.76	15		2.3		2006	08.71		2.0	2006-	21.76	15		2	0060	221
CA	25.98	518			3.1		2006	08.71		CA.	2006-	2598	518		2	0900	221
EP	1856	063									2006-						
	B1	AT.	BE.	BG.	CB,	CY,	CE,	DE.	DK.	EE	E8.	FI.	PB.	dB,	GB,	BU.	IE
		15.	IT.	LI.	LT.	LU.	LW	MC.	ML.	FL	PT.	no.	SE.	SI.	SX.	TR.	AL
		30.	HE.	MK.	YU												
JP	2008	5314	24		T		2008	0814		JP :	2007-	5557	26		2	0300	221
MX	2001	1018	5		- 2		2007	1206		NX:	2007-	1018	5		2	0070	621
TN	2007	TREDE	790		- 2		2007	0928		139	2007-	De26.7	90		2	0070	831
KR	2007	1107	8.4		- 2		2007	1116		KR.	2007-	7218	29		- 2	0070	921
CSS	1011	5125			- 2		2008	0326		C23	2006-	8001	0132		- 2	0070	927
118	2008	0194	565		2.1		2008	0814			2008-						
PRIORIT											2005-						

MO 2006-18349

W 20060221

CASKEACT 145:292717; MARPAT 145:292717

ASSMER 11 OF 20 CAPLUS COPYRIGHT 2008 ACS on STN (Contamoed)

Takle compds. I $[K-(CD2)\eta_1 n-1.5]$, M-(un) pulsetivited alk(en/yn)v], betworkary, etc., K^2-CD2 and derive, (0) and derive, (un) substituted alk(en/yn)v], and and analysis of the state of the s

animals—instructions of the control of the Computer of the Com

iviv. as
 matrix metalloproteinase inhibitors for treating asthma and other
 infiamatory disorders)
17441-19-7 CARUN
18-bearindsscole-7-earboxylic acid,
22-chtony-1[2-12-22-tertarel-1-y1][1.1*-biphenyl]-4-yl]methyl]-(CA

THERE

LO ARSMER 11 OF 20 CAPLUS COPYRIGHT 2000 ACS on STN (Continued)

144 702-48-4 CAPLUS [3,7'-Biphenyi)-2-carboxylic acid, 4-[1,8'-dimethyl-2'-propyl[2,6'-bi-18-benzinidszol]-1'-yl)nethyl]- (CA

REFERENCE COUNTY THERE ARE 2 CIVED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE

LA AMMENA 1 or 20 CANNER CONTROLL THE MET OF THE MET OF

DOCUMENT TYPE: LANGUAGE: FAMILY ACC. NUM. COUR

2006: 1671: R: 2587: 2006:	772 AT, IE, IR, 141	8E, 8I, 15,	CH, 17, 10	DE,	DK,	2006 2006 ES,	0525 0621 PR, MK,	αs,	08 2 EP 2 GR,	004-	2856 1060	53 44		2	0051 0041	121 124
R1 2587: 2006:	AT, IE, IR, 141	8E, 81, 15,	CH, LT, YU	DE, LV,	DK,	28,	PR,	GB,	GR,							
2587	1E, 1R, 141	81, IS,	17,	LV,	27,					77.	7.7		NL.	SE.	MC.	
2006	HR, 141 2568	IS,	YU			ю,	MK,									
2006	141	48		A1					Mile	776	BG,	CZ.	EE.	80.	P2.,	88
2006	0568	48		2.2												
						2006	0601		CA 2	005-	2587	141		2	0051	110
W:				2.2		2006	0601		WO 2	005-	1334	70		2	0051	110
		20.	AL.	AM.	NZ.	207.	AZ.	BA.	nn.	ng.	BR.	266.	BY.	RZ.	CA.	CH.
	C22.	00.	CR.	co.	CZ.	DE.	nr.	TIM.	Dr.E.	EC.	RE.	E3.	RS.	PI.	on.	an.
	ar.	GR.	094	RR.	80.	TD.	77	770.	18.	JP.	KE.	123.	124.	122.	KP.	EE.
	MZ.	No.	193,	NI.	190,	NE.	CH.	PG.	PH.	P2.,	PT.	BO.	BO.	80,	8D,	88.
	50.	530.	52	504.	57.	TJ.	TH.	TN.	TR.	77.	TZ.	UA.	DG.	US.	UZ.	VC.
	777.	YU.	20.	224.	234											
2001	27.	DE.	BG.	CH.	CY.	CZ.	DE.	DX.	EE.	ES.	FI.	FR.	GB.	GR.	HO.	II.
	IS.	17.	1.7.	LU.	LV.	MC.	351	Pl.	PT.	RO.	SE.	51.	SX.	TR.	BF.	BJ.
	CF.	C3.	CT.	CM.	a.	cen.	90.	au.	ML.	MR.	NR.	522	TD.	79.	761.	QH.
1846	409			8.2			1024		EP 2	005-	8241	02		- 2		110
2.1	AT.	BE.	BG.	CH.	CY.	CZ.	DE.	DK.	EE.	255.	FI.	FR.	GB.	GR.	150.	IE.
	15.	27.	1.7.	1/7.	100.	LV	MC.	ML.	P2.,	PT.	20.	55.	51.	5X.	TR	
2008.	5206	44		7		2008	0619		JP 2		5422	55		2	0051	110
1030.	503			- 22		2006	0529		NEL 2	005-	1030	503		2		123
1030	503					2006	1128									
APP	253	IMPO	. 1						EP 2	004-	1060	44		5 2	0041	124
	70%: 1946 R: 2008:	CN, GE, RE, RE, SG, VN, IS, CF, GH, NO, 1846409 R: AT, 15, 20085208	CR, CO, GE, GR, KE, LC, NE, SM, SG, SK, VN, YC, SM: A7, ER, CF, CG, GH, KE, KG, KE, SM,	CE, CO, CE, CE, CE, CE, CE, CE, CE, CE, CE, CE	CR, CO, CR, CU, CG, CG, CG, CG, CG, CG, CG, CG, CG, CG	CH, OO, CH, CH, CH, CH, CH, CH, CH, CH, CH, CH	COL. CO., CO., COL. DE, CO., COL. DE, CO., COL. DE, CO., COL. DE,	COL 05, 05, 08, 01, 02, 05, 08, 05, 08, 05, 08, 08, 08, 08, 08, 08, 08, 08, 08, 08	CSI CO' CSI, CO' CSI, SE, DE S	CHI CO, CHI CO CHI M, DE 104 104 105 104 104 105 104 104 105 105 104 104 105 105 104 105 105 105 105 105 105 105 105 105 105	COL 90, 15, 16, 17, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18	CHI CO. Ch. Ch. CH. CH. CH. SH. M. Mr. SH. SH. SH. MR. MR. CH. SH. SH. SH. MR. MR. CH. SH. SH. SH. SH. SH. SH. SH. SH. SH. S	One of the control of	Cont. Co. 20, 100 11 11 11 11 11 11 11 11 11 11 11 11	COL CO.	280 A.S. 18 A.S. 18 C. 18 C. 17 C. 18 A.S. 18 C. 18 A.S. 18 A.

US 2005-664619P P 20050322 MO 2005-383478

M 20051110

OTHER SOURCE(S): MARPAT 145:8165

12

ANSWER 12 OF 20 CAPLUS COPYRIGHT 2008 ACS on STN (Continues)

The title compds. I [R1 = B, alkyl optionally substituted with hydroxy; X = N, CR9; Y = O, NB; R2-R5 = B, halo, CN, alkyl, etc.; <math>B6 = B, Me; R9 =

В, No) which are histamine N4 receptor ligands and have therefore a number

the production of the production of the treatment of author and liberaria (al., 563)—cells (before and with the production of the producti

B4 receptor ligands) 1057003-32-3 CAPLUS

105 NOS-52-8 CAPLUS
Methanone, [5-brono-7-methyl-18-benzimidazol-2-yl][(2a8,6a8)-hexahydro-5methylpyrrolo[5,4-c]pyrrol-2(18)-yl]- (CA INDEX NOME) Shoolwte stereochemistry.

NN 1057003-34-5 CAPLUS
CN Nethanone,
(5-flooro-7-methyl-18-benzinidazol-2-yl)|(5aR,6aS)-bezahydro-5methylpyrrolo[3,4-c]pyrrol-2(18)-yl]- (CA IRBEX NAME)

Absolute stereochemistry.

801719-07-1927 coloroscopica archivity) NCT (December) SPR (Dymbelic Lat. NCC (December 1)) SPR (Dymbelic Lat. NCC (December 1)) SPR (December 1) SPR (Decem

SSTITS-40-0F EL: FRC (Pharmacological activity); SFN (Synthetic preparation); TRU (Therapeutic use); ETGL (Biological study); FREP (Preparation); USES es) (preparation of octahydropyzrolo[3,4-c]pyzrole derivs. as histamine 84

[preparation or octangurapy, and [preparation of preparation or octangurapy] services of the preparation of

Relative stereochemistry.

AMBNER 12 OF 20 CAPLUS COPYRIGHT 2009 ACB on STN (Continued)

881713-05-7 CAPLUS Methanose, hioro-5-nethyl-18-benrinidarol-2-y1)[(3aR,6aS)-bexahydro-5-nethylpyrrolo(3,4-0]pyrrol-2(18)-y1)-, rel- (CA INDEX NAME)

SETTIP-09-1 CAPLUS Mcthanon, (5-dimethyl-1E-bensinidazol-2-yl)[(348,648)-hexahydro-5-nethylpyrxolo[3,4-0]pyrxol-2(18)-yl]-, rel- (CA INDEX NAME)

seffrm-11-5 CAPLES Mechanome, [(38K,688)-hemmahydro-5-methylpyrrolo[3,4-o]pyrrol-2(18)-yl][6-Hrifilmormethyl)-18-bennimidarol-2-yl]-, rel- (CK INDEX NAME)

LO AMBMER 12 OF 20 CAPLUS COPYRIGHT 2000 ACS on STN (Continued)

887778-99-6 CAPLUS Methanome, (6,7-dunethyl-18-benzinidazol-2-yl)[(7aF,6aS)-hex methylpyrrolo[3,4-c]pyrrol-2(18)-yl]-, rel- (CA INDEX NAME)

887773-01-3 CAPLOS Methanone, [(38,645)-bezahydro-5-methylpyrrolo[3,4-c]pyrrol-2(18)-y1]|7-methyl-18-benzinidanol-2-y1)-, rel- (CA IRMEX NAME) Relative stereochemistry.

221 887779-04-6 CAPLUS CN Nethanone.

CN Methanome, (S-chloro-7-methyl-18-benzimidazol-2-yl)|[3aE,6aS]-hexahydro-5-methylpyzrolo[3,4-c]pyzrol-2(18)-yl]-, zel- (CA IMDEX NAME) Relative stereochemistry.

LO ANSWER 12 OF 20 CAPLUS COPYRIGHT 2000 ACS on STN (Continued)

887779-12-6 CAFLOS 18-Bantinidarole-6-carboxylic acid, 2-[[7aR,6aS]-basabydro-5-methylpyrrolo[3,4-c]pyrrol-2(18)-yl]carbonyl]-, rel- (CA. HOKK NUME)

Relative stereochemistry

887779-16-0 CAPLUS

DBTYT=22-0 Caraco Methanon, lsoro-5-methyl-18-benzimidazol-2-yl)[{3ak,6a8}-benahydro-5-methylpyrrolo[3,4-o]pyrrol-2(18)-yl]-, rel- (CA INDEX NAME)

887779-25-1 CAPLUS Methanore, (5,7-dimethyl-18-benzinidarol-2-yl)[(3aR,6a8)-benzhydro-5-methylpyrrol-3,4-e)pyrrol-2(18)-yl]-, rel- (CA INDEX NAME)

887779-27-3 CAPLUS Methazowe, [5-fixoro-7-(trifixoromethyl)-18-benzinidazol-2-yl)| [7aR,6a8)-benshydro-5-methylpyrrolo]3,4-e)pyrrol-2(18)-yl)-, rel- (CA INNEX NAME)

ANSWER 12 OF 20 CAPLUS COFFRIGHT 2008 ACS on STN (Continued)

887779-37-5 CAPLUS
IE-Benzinidarole-2-methaninime, w-[[JaR,6a2]-hexabydxo-5-methylpyxrole/3,4-o]pyxrol-2(18)-yl]-7-methyl-, rel- (CA INDEX NUME)

887173-33-7 CAPUS 1R-Benrinidarole-2-methaninine, 6-fluoro-x-|(3aR,6a5)-hexahydro-5-methylpyrolo[3,4-c]pyrrol-2(1R)-yl]-7-methyl-, rel- (CA INDEX NUME) Relative stereochemistry.

887779-40-0 CARLTS
1N-Bentzmidarole-2-methaninime, 6-chloro-q-|(3aR,6aS)-hexahydro-5methylpyxxolo[3,4-0]pyxxol-2(18)-y1]-7-methyl-, rel- (CA IMDEK NAME)

LO AMBMER 12 OF 20 CAPLUS COPYRIGHT 2000 ACS on STN (Continued)

BBTTTS-IG-G CAPLUS

Methanone,
hloro-5-methyl-18-benzimidazol-2-yl) [(7ak,6aS)-bezahydro-5methylpyzrolo|3,4-c]pyzrol-2(18)-yl)-, rel- (CA INDEX NAME

887779-31-9 CAPLOS 18-Benzinidarole-6-curbomitrile, 2-[|[GAR,648]-bexshydro-5-methylpyrrol[3,4-0]pyrrol=2(18)-yl]carbomyl]-, rel- (CA INDEX NAME)

887779-32-0 CAFLOS Methanome, [6-fluoro-5-(trifluoromethyl)-1E-benzimidazol-2-yl][(3aR,6a5)-hexahydro-5-methylpyzrolo(3,4-o)pyzrol-2(18)-yl]-, zel- (CA INDEX NAME) Relative stereochemistry.

LO ANSWER 12 OF 20 CAPLUS COPYRIGHT 2000 ACS on STN (Continues)

99459-47-9 CAPLUS 18-Benzimidazole-2-carboxylic acid, 6-methyl- (CA INDEX NUME)

673487-21-5 CAPLUS 18-Benzinidazole, 7-methyl-2-(trichloromethyl)- (CA INDEX NAME)

673487-33-7 CAPLUS 1H-Bentinidarole, 2-(trichloromethy1)-6-(trifluoromethy1)- (CA INDEX NAME)

18 ANSMER 12 OF 20 CAPLUS COPTRIGRT 2008 ACS on STN (Continued)

795296-06-9 CAPEARS IB-Benzinidarole-G-carbonylic acid, 2-(trichloromethyl)-, methyl ester (CA INDEX NAME)

22 073669-16-0 CAPADS
CN 1E-Benishidarole, 6-fluoro-7-methyl-2-(trichloromethyl)- (CA INDEX NAME)

873669-20-6 CAPLUS 18-Denzimidarole, 7-chloro-i-methyl-2-(trichloromethyl)- (CA INDEX NAME)

887779-48-8 CAPLUS 1E-Benrinidarole, 5-chloro-7-methyl-2-(trichloromethyl)- (CA INDEX NAME)

LS ANSWER 13 OF 20 CAPLIS
ACCESSION NUMBER: 2000
DOCUMENT NUMBER: 144
TITLE: Proj

Sizes Companion 3008 McG on STI 2005;435046 Cases State Sta

Schoenen,

Frank J.; Vanvliet, David N.; Middlemiss, David N. Noads, LLC, USA PCT Int. Appl., 64 pp. CODEN: PINCES Parent

PATENT ASSIGNAL(S):

English 1

DOCUMENT TYPE: LANGUAGE: FAMILY ACC. NUM. COUNT: PATENT INFORMATION:

	TEST						DATE				ICAT						
500	2006	0500	53		A2		2006	0511			005-					0051	
wo	2006						2006										
	M s						200,										
							DE.										
							ID,										
		EZ,	LC.	LK,	LR.	1.8,	1.7,	100,	LV.	LY,	MA.	MD,	MG,	MK,	MOI,	MM,	MX,
		MZ,	MA.,	303,	MI,	300,	ME,	CM,	PG,	DE,	PL,	PT,	no,	BU.	SC,	SD,	5E,
		50,	SX,	51.,	524,	SY,	TJ,	TM,	TN,	TR,	TT,	TZ,	UA,	UG,	US,	UZ,	VC,
		1777,	YU,	22.	234,	234											
	2001	27,	BE,	DG,	CE,	CY,	CZ,	DE,	DE,	EE,	ES,	FI,	FR,	GB,	GR,	HU,	IE,
		18.	77.	1.7.	100.	LV.	MC.	NL.	P2.,	P7.	BO.	SE,	SI.	sx,	TR.	BF.	BJ,
		CT.	03,	CI.	CH,	93,	GRZ,	90,	GNI,	ML.	MR.	NE.	800,	TD.	TG.	BM.	GB,
		GM.	KE.	1.8.	MV.	MZ,	185.	SD,	81.,	82,	TE.	03,	221,	256	221,	22.	BY.
		203.	EZ.	MD.	207	23.	721										
AC.	2005	30.25	19		A2		2006	0511		NO 2	005-	3025	19		- 2	0051	027
CA	2585	766			8.2		2006	0511		DA 2	005-	2585	766		- 2	0051	027
EP	1812	451			3.2		2007	0801		EP 2	005-	8137	62		- 2	0051	027
	2.1	AT.	BE.	DG.	CE.	CY.	CZ.	DE.	DE.	EE.	ES.	FI.	FR.	GB.	GR.	MO.	IE.
		10	777	1.7	1.77	7.17	1.07	MO	307	101	107	200	0.0	OT	ov.	770	
TR	2008	1100	22		- 72		2002	ocos.		TR O	007-	5791	45		- 0	00.51	022
LIORIT'	Y 100	1.50	THERO							74 0	004-	6240	5.79		p 0	0041	101
																00.51	

OTHER SOURCE(S): CASREACT 144:468167; MARPAT 144:468167 ANEMER 12 OF 20 CAPLUS COFFRIGHT 2008 ACS on STN (Continued)
(Deactant or respent)
(preps. of octahydropyrrolo[3,4-c]pyrrole derivs. as histanine H4
receptor lipands)
CAPLUS CAPLUS

18-Benzimidazole, 6,7-dimethyl-2-(trichloromethyl)- (CA INDEX NAME)

LO ANSWER 13 OF 20 CAPLUS COPYRIGHT 2000 ACS on STN (Continued)

The title compde, I on II is a He of C (the provise that 50 is sheen the he in) $N = O_0$ (or a hous) r = A(k)r, evolutily, anyly step; r = A(k), r = A(k)r), and r = A(k) (or in) r = A(k), r = A(k)

y
determining inhibition of THF-s production by FMSC. Pharmaceutical
formulations comprising the compound 1 or II are disclosed:
085712-03-08 085712-03-08 085712-03-08 085712-03-08 08712

[Uses]
[Inter]

886752-83-6 CAPLUS Boronza and, B-15-15-oyano-2-(4-methoxyphenyl)-18-benzunidazol-1-yl]pentyl]- (CA INDEX NAME)

MISSIER 13 OF 20 CAPLUS COPTRIGHT 2008 ACS on STN

Goronic acid, B-[5-[6-cyaro-2-(6-methoxyphenyl)-18-benzinidarol-1-yl[penyl]- (CA INDEX NAME)

582-60-5, 5,6-Dimethylbenzimidazole Ris ECT Deactantly RACT (Reactant or reagent) (preparation of benzimidazole boronic acids and their analogs for | [preparation of bentinisation professional waves was analysis and manhisting afficient yet of the such as tumor necrosis factor alpha (TE-4) | 125 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 |

- AMBREA 14 OF 10 CARLING COMPRISES 2008 ACS on STH (Continued)
 Indicate labels they) TSSS (Versa)
 (Allane labels for therapeutic use)
 1450-149-5 CATAMIC action (2-1-theraplearbony)-18-bensinidasol-2-yl]-, methyl acter (CA INEXEX NAME)

PATENT ASSIGNAE(S): GPC Biotech, Inc., USA PCT Int. Appl., 201 pp. CODEN: FIEED2 DOCUMENT TYPE: NO LANGUAGE: E: EMMILY ACC. NUM. COUNT: 1 PATENT INFORMATION: PATEST NO. KIND DATE APPLICATION NO. | SATE | MATERIAL | MA WO 2005-0821843 W 20050617 MARPAT 144:101073 The invention pertains to inhibitors of various kinases (e.g. 8/7 nes, Tyr Kinssez, etc.), which inhibitors were previously known as eyelin-dependent kinsse inhibitors (CDW). The inhibitors of the Minssez, including dray-resistant forms of metant kinssez. Thus, the kinssez inhibitors are useful in treatup a wide range of diseases/conditions associated with amornal functions/recessive diseases/conditions associated with amornal functions/recessive vities of the target kinases, including metant kinases. The invention further provides methods for treating cancers, tumors, and patients which are resistant or refractory to other therapsutus agents. Pharmaceutical compan, and packaged pharmaceuticals with instructions of these inhibitors and methods of using these inhibitors. also provided. 31430-18-9, Nocodazole RL: PMC (Pharmacological activity), THV (Therapeutic use), BICL CALCAR CONTRIGHT 2008 ACS on STR
1412-14000
1412-14000
1412-14000
1412-14000
1412-14000
1412-14000
1412-14000
1412-14000
1412-14000
1412-14000
1412-14000
1412-14000
1412-14000
1412-14000
1412-14000
1412-14000
1412-14000
1412-14000
1412-14000
1412-14000
1412-14000
1412-14000
1412-14000
1412-14000
1412-14000
1412-14000
1412-14000
1412-14000
1412-14000
1412-14000
1412-14000
1412-14000
1412-14000
1412-14000
1412-14000
1412-14000
1412-14000
1412-14000
1412-14000
1412-14000
1412-14000
1412-14000
1412-14000
1412-14000
1412-14000
1412-14000
1412-14000
1412-14000
1412-14000
1412-14000
1412-14000
1412-14000
1412-14000
1412-14000
1412-14000
1412-14000
1412-14000
1412-14000
1412-14000
1412-14000
1412-14000
1412-14000
1412-14000
1412-14000
1412-14000
1412-14000
1412-14000
1412-14000
1412-14000
1412-14000
1412-14000
1412-14000
1412-14000
1412-14000
1412-14000
1412-14000
1412-14000
1412-14000
1412-14000
1412-14000
1412-14000
1412-14000
1412-14000
1412-14000
1412-14000
1412-14000
1412-14000
1412-14000
1412-14000
1412-14000
1412-14000
1412-14000
1412-14000
1412-14000
1412-14000
1412-14000
1412-14000
1412-14000
1412-14000
1412-14000
1412-14000
1412-14000
1412-14000
1412-14000
1412-14000
1412-14000
1412-14000
1412-14000
1412-14000
1412-14000
1412-14000
1412-14000
1412-14000
1412-14000
1412-14000
1412-14000
1412-14000
1412-14000
1412-14000
1412-14000
1412-14000
1412-14000
1412-14000
1412-14000
1412-14000
1412-14000
1412-14000
1412-14000
1412-14000
1412-14000
1412-14000
1412-14000
1412-14000
1412-14000
1412-14000
1412-14000
1412-14000
1412-14000
1412-14000
1412-14000
1412-14000
1412-14000
1412-14000
1412-14000
1412-14000
1412-14000
1412-14000
1412-14000
1412-14000
1412-14000
1412-14000
1412-14000
1412-14000
1412-14000
1412-14000
1412-14000
1412-14000
1412-14000
1412-14000
1412-14000
1412-14000
1412-14000
1412-14000
1412-14000
1412-14000
1412-14000
1412-14000
1412-14000
1412-14000
1412-14000
1412-14000
1412-14000
1412-14000
1412-14000
1412-14000
1412-14000
1412-14000
1412-14000
1412-14000
1412-14000
1412-14000
1412-14000
1412-14000 INVENTOR (S): PATENT ASSIGNEE(S): DOCUMENT TYPE: LANGUAGE: FAMILY MCC. NUM. COM PATENT INFORMATION: PATERT NO. KIND DATE APPLICATION NO. PRICETTY APPLAL TREE . MO 2004-055247 A 20040220 US 2005-546304 A2 20050819 US 2006-792127P P 20060413

Duralized are ati-CPD artibobias and serve. Heard respected to a pharaceristic control of the co

LS ANSMER 14 OF 20 CAPLUS COFFRIGHT 2008 ACS on STN ACCESSION NUMBER: 2006:13464 CAPLUS DOUBLEST NUMBER: 144:101073

therapeutic uses of kinese inhibitors, and compositions thereof Galagaura, Maureen G.; Kley, Nikolai A.; Northi, Krishna K.

AMENER 16 OF 20 CAPLUS COPYRIGHT 2008 ACS on STN

Dabenzosuberone derivs., such as I |X = CE2; K, R1 = E, CE, CN, balogen, alkowy, sulfonylamino, amimo, etc.; R2 = aryl, beteroaryl; R3 = B, alkyl],

and heterocyclic analogs thereof, such as I [X = 0, 5, NE, NMe, etc.],
were prepared for therapsviic use in the treatment of pathol. disorders
acceptible to steroid hormone muclear receptor modulation. These

is.

are claimed for use the treatment of disorders, such as Conn's Syndrome, are claumed for use the treatment of clausedees, such as Council Syndroms. As the council of the

with organ transplant, malignancies such as leukomias and lymphomas,

address! insufficiency, compensate adress! hyperplassa, chemistic fever, polystressian nodess, granicestour polystressian, substates of mysload regulation, upper collection, and the properties of the properties

ai hyperplazia, cerebrai edems, thrombocytopenia, and little's syndroms, systemic inflamation, inflamatory bound disease, systemic input grant of the control of the contro

LS ANSMER 16 OF 20 CAPLUS ACCESSION NUMBER: 200 PLUS COPTRIGHT 2008 ACS on STN 2004:515475 CAPLUS 141:71360 Available
Preparation of derivatives of and analogs of
dibenzoraberone for use in pharmaceutical
compositions as steroid hormone nuclear receptor
modulators. modilators Coopling, Michael Josephy Green, Josethan Edwardj Green, Josethan Edwardj Green, Jinchia Robertj Green, Timothy Alam, Jadhaw, Frabhalar Romásja Matthews, Bonald Wall Fitchberg, Mitchell Irvin/ Falos, Sevan Fobert, Bell, Michael Gregory Eli Lilly and Coopany, USA
RT Int. Appl., 457 pp.
CODER, FIXED. PATENT ASSIGNMENTS: DOCUMENT TYPE: LANGUAGE: FAMILY MCC. NUM. COUNT: FATENT INFORMATION: | No. PATERT NO. KIND DATE APPLICATION NO JP 2004-559025 CN 2007-10112172 US 2004-517010 Å Å1 B2 IN 2004-RN1910 20041213 RK 2004-PA12998 20041217 TA 2004-10293 20041217 NO 2005-297 20050125 US 2002-791992P P 20020626 PRIORITY APPLE. IMPO. : CN 2003-815098 WO 2003-0516213 W 20030613

ARRIAN 16 (2) CARLON CONTROL TOTAL STATES TO ANY A CONTROL TOTAL STATES AND ANY ASSESSMENT OF THE ARRIVANT ANY ASSESSMENT OF THE ARRIVANT ANY ASSESSMENT OF THE ARRIVANT ASSESSMENT OF THE ARRIVANT ASSESSMENT OF THE ARRIVANT ASSESSMENT ASSESSMENT OF THE ARRIVANT ASSESSMENT ASS

MARRAY 141-71360

OTHER SOURCE(S):

(Therapeutso use), BIOL (Biological study); PREP (Preparation); USES cs) (preparation of derivs, and heterocyclic analogs of dibenzosuberone

[preparation of uncare, uncare, continued to prepare unclear receptor modelators]

120 120-140-150 (2012)

121 120-140-150 (2012)

122 123 (2012)

123 124 (2012)

124 (2012)

125 (2012)

126 (2012)

127 (2012)

128 (2012)

128 (2012)

128 (2012)

128 (2012)

128 (2012)

128 (2012)

710 744-04-0 CAPLUS (28-Benninidaro)-2-one, 5-[(2,8-difluoro-10,11-dibydro-58-dibenzo[a,d]cyclohepten-5-ylldane)nethyl]-1,3-dibydro-1-[2-(4-eorpholisyl)-thyl)= (CA. INDEX NAME)

722 710344-05-1 CAPLUS
CN 28-Benrinidaroi-2-one, 5-[{2,8-difluore-10,11-dihydro-58-dihero[a,d]eyelobeyten-5-ylidene)nethyl]-1,3-dihydro- (CA INDEX NAME)

710344-04-2 CAPLUS
 28-Benninidard-2-one, 5-[(2,8-diffuoro-10,11-dibydro-58-dibearo [a, d) eyelohepten-5-yildene | net hyll -1, 2-dibydro-1-[3-(4-norphoinyl)propyl)- (CA 1808X 1886)

LO ANSMER 16 OF 20 CAPLUS COPYRIGHT 2000 ACS on STN (Continued)

RN 710344-08-4 CAPLES CN 18-Benzingdarole, 6-[10,11-dihydro-58-dibenzo[a,d]gyclohepten-5yliden/nerbyl) = (CA INDEX NAME)

283 710344-10-8 CAPLES
CEN 18-Benzimidarol-2-amine, 6-[{10,11-dihydro-58-dibenzo[a,d]cyclohepten-5-ylidenojmethyl] (CA_INDEX_NAME)

281 710344-13-1 CAFLUS
CH ZE-Bent inidatol-2-one, 5-[(E)-(2-fluoro-10,11-dihydro-5H-dibenzo [a,d]oyolobepten-5-ylidene)nethyl]-1,3-dihydro- (CA INDEX NAME)
Double bond genetty as shown.

18 ARSMER 16 OF 20 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

PN 710744-14-2 CARUNS
CN 22-3-2entinidatol-2-one, 5=[(E)-(2-fluoro-10,11-dihydro-58-dihezor(a,d)pyclohyten-5-ylidene)nethyl)-1,3-dihydro- (CA INDEX NAME)
Double bond geometry as shown.

NN 710344-11-5 CAPUNS
CN ZE-Zenzanidatol-Z-ome, 5-((E)-(2-(difluoromethyl)-10,11-dihydro-5H-dibenol,4d)dycloptem-5-ylidene]methyl)-1,3-dihydro- (CA INDEX NAME)
Double bond geometry as shown.

F21 710344-39-6 CAPUNS C31 28-benzumdazol-2-one, 5-[(B)-[2-(d)flooronethyl)-10,11-dihydro-5Hdibenzumdazol-2-one, 5-[(B)-[2-(d)flooronethyl)-1,3-dihydro- (CA INDEX NAME) 18 ANSMER 16 OF 20 CAPLUS COPYRIGHT 2008 ACS on STN (Continued) Double bond grometry as shown.

NN 710344-19-7 CAPLUS
CN 28-Bent inidatel-2-one, 5-[(10,11-dihydro-58-dimento[a,d]eyelohepten-5ylidene hethyl]-1,3-dihydro-1-methyl- [CA INDEX NAME)

NN 710344-20-0 CAPLUS
SN-Dibenro[a,d]cyclobeptene-2-carbonitrile,
5-[12,3-dibydro-2-oxo-1N-benrinidaro1-5-y1)methyleme)-10,11-dibydro-,
[52]- (CA NEROX NUME)

louble bond geometry as shown.

89 710344-21-1 CAPLOS 29 58-Dibenzo(a, d) gycloheptene-2-carbonitrile, 5-[(2,3-dibydro-2-coxo-18-benzimidazol-5-yllmethylene]-10,11-dibydro-, (58)- (CA IRREX NAME) 18 ARRMER 16 OF 20 CAPLUS COPTRIGHT 2008 ACS on STN (Continued) Double bond occmetry as shown.

CAPLUS
tol=2-one, 5-[(2,8-difluoro=10,11-dihydro=5mtyclohepten=5-ylidene)nethyl]-1,3-dihydro-1-nethyl- (CA

710344-26-6 CAPLOS 2E-Baramidasol-2-one, $5-[(2)-(2-\mathrm{Eluoro}-10,11-\mathrm{dihydro}-5B-\mathrm{dibenz})$ (CA dibenz (a,4) cyclohepten-5-ylldene)nethyl)-1,2-dihydro-1-methyl- (CA INDEX NAME)

Double bond geometry as shown.

18 ARRER 16 OF 20 CAPURS CONTRIGRT 2008 ACS on STN (Continued) disease [a,d]cyclohepten=5-ylidese)methyl]=1,3-dihydro- (CA INDEX NAME)

710344-31-3 CAPLUS
ZE-Beninidarol-2-one, 5-[(E)-(4-chloro-10,11-dihydro-5H-dibenio|a,d]oyclohepten-5-ylidene|methyl]-2,3-dihydro- (CA INDEX NDME) Double bond geometry as shown.

710344-35-7 CARUNS 28-Benzumidatol-2-one, 5-[(1,9-difluoro-10,11-dihydro-58-dibenzo[a,d]gyelohepten-5-yladene)methyl]-1,7-dihydro- (CA INDEX NAME)

921 710344-37-9 CAPLUS

ANGMER 16 OF 20 CAPLUS COFFRIGHT 2048 ACS on STN (Continued)
719344-27-7 CAPLUS
2H-Benzinidarol-2-one, 5-[4E)-(2-Eluoro-10,11-dihydro-5Hdibemzo[a,d]cycloheptem-5-ylidene/methyl]-1,3-dihydro-1-methyl(CA

NUMBE

Double bond geometry as shown,

710344-28-8 CAPLUS 28-ben: middrol-2-one, 5-[{2,4-difluoro-10,11-dihydro-58-dibenzo[a,d]cyclohepten-5-ylldene)nethyl]-1,3-dihydro- (CA INDEX NAME)

710344-29-9 CAPLUS
28-Benzinidazol-2-one, 5-[(2,8-difluoro-10,11-dihydro-58-dibenzola,d)cyclohepten-5-ylidene)methyl)-1,3-dihydro-1-[1-methylethyl)-(CA_INDEX_BMMS)

710344-30-2 CAPLUS 28-Benzimidazol-2-one, 5-[(2)-(4-chloro-10,11-dihydro-58-

L8 ANSMER 16 OF 20 CAPLOS COPFRIGHT 2008 ACS on STN (Continued)
CN 28-Benzinidazol-2-one, 5-[15:-[10,1]-dihydro-2-(trifluoroethy)]-55dibenco (a d)cyclobyten-5-ylden plenty)]-1,7-dihydro- (CA IDEEN N Double bond geometry as shown.

710344-38-0 CAPLUS 28-Benimidsonl-2-ome, 5-[{Z}-[10,11-dihydro-2-(trifluoromethyl)-5R-dibeno[a,d]cyclohepten-5-ylidens[methyl]-1,3-dihydro- (CA INDEX NAME) Double bond geometry as shown

710344-51-7 CAPLUS
28-Benzinzdarol-2-one, 5-[(E)-(8-fluoro-10,11-dihydro-58-benzo[4,5]opolobepta[1,2-b]pyridin-5-ylidese)methyl]-1,2-dihydro- (CA

Double bond geometry as shown

L8 AMENER 16 OF 20 CAPLUS COPTRIGHT 2008 ACS on STN (Continued)

710344-75-5 CARLUS
2E-Dennaridacol-2-ore, 5-[(8-Eluoro-10,11-dahydro-5H-bennaridacol-2-ore, 5-[(

710345-27-0 CAPLUS 28-Peninidsrol-2-one, 5-[(4,5-dibydro-10B-benro[4,5]cyclohepta[1,2-dib)dro- [CA INDEX NAME)

710345-35-0 CAPLNS
28-Bensinidarol-2-one, 5-|(E)-(7-fiboro-4,5-dihydro-108-bensi(4,5)opolobeyta[1,2-d]thiazol-10-ylidene)methyl]-1,2-dihydro- (CA INDEX SAME)

AMBMER 16 OF 20 CAPLUS COPTRIGHT 2008 ACS on STN (Continued)

710345-66-7 CARAUS 2E-Benzinidazol-2-one, 1-cyclopropyl-5-|(8-fluoro-10,11-dihydro-58-benzo[4,5]cyclobepta[1,2-b]pyridin-5-ylidene)methyl)-1,3-dihydro- (CAROEX NME)

//IDIA-04-0 CAMUTS
28-Bentinidasol-2-one, 5-[(8-fluoro-10,11-dihydro-58-benro[4,5]cyclobepta[1,2-b]pyridan-5-ylidene)methyl]-1,3-dshydro-1-[2-(4-morpholinyl)tehyl)- (CM_NUMEX_NUMEX)

710345-76-9 CAPLIS
28-Banzanidarol-2-one, 5-[(3-fluorodibanz[b,e]oxepin-11(68)ylidean(psebyl)-1,3-dibydro-1-[2-(4-eorpholinyl)etbyl)- (CA INDEX NUME)

L8 AMEMER 16 OF 20 CAPLUS COFFRIGHT 2008 ACS on STN (Continued) Double bond geometry as shown.

710345-37-2 CAPLUS
2B-Benninidatol-2-one, 5-[{z}]-(7-fluoro-4,5-dihydro-10E-benno[4,5]cyclohepta[1,2-d]tharol-10-ylideno]methyl]-1,3-dihydro- (CA
RUDEX NAME) Double bond geometry as shown

710345-64-5 CAPLUS
5H-Bence(4,5)cyclohepta[1,2-b]pyridine-2-carbonitrile,
5H-Bence(4,5)cyclohepta[1,2-b]pyridine-2-carbonitrile,
5-[1,2,3-d]hydro-2-cono-18-bencinidarol-5-yl)nethylene}-8-fluoro-10,11-dihydro- (CA INDEX NOME)

710345-65-6 CAPLOS
28-BenInidatol-2-one, 5-[48-Cluoro-10,11-dihydro-58-benzo[4,5]polospata[1,2-b]pyridin-5-ylidene)methyl]-1,3-dihydro-1-(1-methylethyl)- (CA INDEX NAME)

ANSWER 16 OF 20 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

710345-77-0 CAPLUS
28-Benzinidasol-2-one, 5-[(2-fluorodibenz|b,e)omepin-11(6E)ylidene)methyll-1,2-dibydro-1-[3-(4-morpholinyl)propyl]- (CA INDEX NAME)

730.545-76-4
28-Benzinidazol-2-one,
clopropyl-5-|(2-fluorodibenz|b,e]omepin-11(68)
ylidene)methyl]-1,3-dibydro- (CA INDEX NOME)



710345-79-2 CAPAUS 2B-Benzimidazol-2-one, 5-[{2-fluorodibenz[b,e]onepin-11[68]-ylidene)methyl]-1,3-dibydro- (CA_IMDEX_NAME)

710345-80-5 CAPQUS 28-Benrindarol-2-one, 5-[(3-fluorodibens[b,eloxepin-11(68)-ylideze|hortyl]-1,3-dibydro-1-(1-methylethyl)- (CA_INDEX_NAME)

710345-81-6 CAPLUS 2E-Benrinidarol-2-one, 5-[(3,8-difluorodibenz[b,e]onepin-11(68)-ylidozolustly1]-1,3-dihydro- (CA INDEX NAME)

71G345-82-7 CAPLUS 28-Benzanidazoi-2-one, 5-[(2-chlorodibenz[b,e]omepin-11(68)-ylidene)nethyl)-1,3-dihydro- (CA INDEX NAME)

710345-83-8 CAPLES
2B-Benginidarol-2-one, 5-[{7,7-difluorodibeng[b,e]omepin-11(68)-ylidene)methyl}-1,3-dihydro-1-[2-(4-morpholinyl)ethyl}- (CA IRDEN NAME)

LO ARSMER 16 OF 20 CAPLUS COPYRIGHT 2000 ACS on STN (Continued)

710345-84-9 CAPLUS 2B-Benzinidarol-2-one, 5-[(3,7-difluorodibenz[b,e]osepin-11(6B)-ylidene/nerbyl]-1,3-dibytro- (CA INDEX NAME)

RN 710345-85-0 CAPLUS
CN 28-Benzimidatol-2-one, 5-[(3,8-difluorodibenz[b,e]oxepin-11(68)ylidenejnethyl]-1,3-dihydro-1-[2-(4-morpholinyl)ethyl]- (CA INDEX NAME)

ANSWER 16 OF 20 CAPLUS COFFRIGHT 2009 ACS on STN (Continued)

Double bond geometry as shown.

| 710745-86-1 CARLES | CREATE | CREATE

710345-92-9 CAPLUS ZE-Bezzinidarol-2-one, 5-[(8-fluoro[1]benroxepino[3,4-b]pyzidin-5(llE)-ylidens/benryl-2-1,3-ddhydro- (CA INDEX NOME)

710345-93-0 CAPL/US 28-Banzanidaro1-2-one, 5-(dibenz(b,e]oxepin-11(68)-ylidenemethyl)-1,3-dibydro- (CA INDEX MAME)

LO ANSWER 16 OF 20 CAPLUS COPYRIGHT 2000 ACS on STN (Continued)

710346-00-2 CAPLUS 2H-Benrinidarol-2-one, 5-[(Z)-(3-Elworodibenz[b,e]oxepin-11(6H)-ylidene)entlyl]-1,3-dibydro-1-methyl- (CA IRREX NAME) Double bond geometry as shown.

710346-01-3 CAFLUS 2B-Benzimidari-2-one, 5-[(E)-(3-Elworodibenz[b,e]osepan-11(6B)-yladospinetbyl]-1,3-dahydro-1-metbyl- (CA INDEX SUME) Double bond geometry as shown.

710346-04-6 CAPLES 2H-Bentinidarol-2-one, 1,3-dihydro-5-[{3-methoxydibenz[b,e]oxepin-11(EH)-ylidene)methyl]- (CA INDEX NOME)

730 730346-06-8 CAPLUS CH 28-Bergindarol-2-one, 5-[(8-chlorodibens[b,e]oxepin-11(68)-ylidexe)mothyl-1,3-ddhydro- (CA INDEX NOME)

723 710346-07-9 CAPLUS CN 28-Seminidazol-2-one, 5-[(4-fluorodibenz[b,e]omepin-11(68)ylademohenbyl]-1,7-dihydro- (CA INDEX NAME)

23 710346-08-0 CAPLUS 23 28-Beninidatol-2-one, l,3-dihydro-5-[[3-|txxfluoromethyl)dihemi[b,e]oxepin-11(68)-ylidene]methyl]- (CA INDEX NUME) LO AMSMER 16 OF 20 CAPLUS COPYRIGHT 2000 ACS on STN (Continued)

EN 710346-09-1 CAPLUS CN 28-Benzimidatol-2-one, 5-[(3-fluoro-6,11-dihydrodibenz[h,e]oxepin-11yl)nethyl)-1,3-dihydro- (CA INDEX NAME)

PR 710346-10-4 CAPLES
CR 28-Benzinidazol-2-one, 5-[(3-fluorodibenz|b,e]osepin-11(68)ylideno|nethyl]-1,3-dibydro-1-[2-(1-pyrrol/displothyl)- (CA INDEX NAME)

RN 710346-11-5 CAPLUS
CN 28-Benzinidazol-2-one, 5-[(3-chlorodibenz[b,e]ouepin-11(68)-ylidesolnethyl]- (CA INDEX NAME)

L8 ANSMER 16 OF 20 CAPLUS COFFRIGHT 2008 ACS on STN (Continued)

732 710346-12-6 CAPLUS CD 2E-Zenzinidarol-2-ore, 5-[(3-fluorodibenz[b,e]oxepin-11(68)ylideze)nebby]-[-]-3-dibydro-1-[2-(1-pipezidisyl)etby]- (CA INDEX NAME)

- CANADA - C

R) 710346-64-8 CAMUNS
CH 2E-Tentinidatol-2-one, 5-[(2)-(3-fluorodibent[b,e]oxepin-11(6H)-ylidenberhyl]-1,7-dibytro-1-(2-nethylpropyl)- (CA INDEX NAME)
Touble bond geometry as abown.

LO ANSWER 16 OF 20 CAPLUS COPYRIGHT 2000 ACS on STN (Continues)

FN 710346-65-9 CAPLUS
CN 28-Benzimidazol-2-one, 5-[{7-fluorodibenz[b,e]osepun-11(68)-ylideobethyl]-1,3-dibytro- (CA INDEX NUME)

RN 710346-66-0 CAPLUS
CN 28-Benzinidazol-2-one, 5-[(9-fluorodibenz[b,e]osepin-11(68)-ylidene)methyl]-1,3-dihydro- (CA INDEX NAME)

38 710346-67-1 CAPLUS CH 2B-Bentinidatol-2-come, 5-[(E)-(9-chlorodibens[b,e]oxepin-11(6H)-ylidensumbty]1-3,3-dibydro- (CA INDEX NUME) Double bond geometry as shown. AMSMER 16 OF 20 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

710346-68-2 CARLUS ZE-bentmidato1-2-one, 5-[(2)-(9-chlorodibent[b,e]oxepin-11(6E)-ylideselnethyl)-1,J-dibydro- (CA INDEX MME) louble hond geometry as shown.

710346-69-3 CAPLUS 2E-Bennandarol-2-one, 5-[(3-fluorodibens[b,e]oxepin-11(68)-yladese)methyl)-1,7-dibydro-1,3-dimethyl- (CA INDEX NAME)

NO 710746-70-6 CAPLUS CN 28-Renamidatol-2-one, 5-(20-(7-15/00-6))-1,4-d)thiatol-10(48)-ylidene)nethyl)-1,7-dlhydro-1-(2-(4-norpholinyl)-thyl)- (CA INDEX NAME)

ANSWER 16 OF 20 CAPLUS COPYRIGHT 2008 ACB on STN (Continued)

710347-81-2 CAPLUS 22-Benzinidate1-2-one, 5-[(52)-1-[3-Elworodisenz[b,e]oxepin-11(68)-ylidene/ethyl]-1,3-dihydro- (CA INDEX NAME) louble bond geometry as shown.

LS ANSMER 16 OF 20 CAPLUS COFFEIGHT 2008 ACS on STN (Continued) Double bond geometry as shown.

| RE | 710346-71-7 CAPUSE CB | 2B-Bent midstoil-7-ose, 5-[(E)-(7-flworo[])bencomept | [3,4-d]thistoil-10(4E)-yliden.pethyll-7-dibydro-1-[2-(4-morpholisyl)ethyl]- (CA INDEX NAME) Double bond geometry as shown.

710347-80-1 CAPLES 2B-Bentinidarol-2-one, 5-[{SE})-1-[3-flworedibenz[b,e]oxepin-11{EE}-ylidene)ethyl]-1,3-dibydro- (CA IRSEX NAME) Double bond geometry as shown.

LS ANEMER 17 OF 20 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2003:991486 CAPLUS
TOCKHERT NUMBER: 1401:7827
TITLE: Preparation of benzimidazole derivatives which

the cytokine or biological activity of macrophase migration shibitory factor (NIT) cortical Pay. Magny Wagnib Cortical Pay. Ltd., Meseralia FCT Int. Appl., 149 pp. COMENT PIXED.
English

	TEST										ICM					NTE	
	2003																
w																	
	W1										BC,						
											EE,						
											ms,						
											No.						
											sx,		TJ,	TN,	TN,	TR,	TT,
											SN,						
	25M s										TE,						
											CB,						
											NL,						
											GW,						
	2487																
NO	2003		44		3.2		2003			NO 2	2003-	2332	44		2	0030	303
	2405									GB 2	2004-	2724	2		2	0030	303
	2405																
EP	1511	736			8.1		2005	0309		EP 2	2003-	7270	10		- 2		909
	R.	NT.	BE,	CB,	DE.	DK.	ES,	PR.	GB,	GB,	17,	LI.	LU.	NL.	SE,	MC.	PT.
		IE,	SI.	LT.	LV.	PI,	BO,	MK,	CY,	AL,	TB,	BG,	CE,	EE,	BU.	88	
CN	1675	185			A		2005	0928		CR 2	2003-	8189	35		- 2	0030	808
JP	2005	5330	42		T		2005	1104		JP :	2004-	5112	73		2	0030	303
NZ	5373	01			A		2006	0630		355 Z	2003-	5373	01		2	0030	303
IN	2004	32301	040				2006	0804		122 2	2004-	2118	40		2	0041	206
23.	2004	0098	45				2006	0927		23. 2	2004-	92.45			2	0041	206
(78	2006	0154	977		8.1		2006	0712		08 2	-2005	51.72	6.4		2	0050	920

MU 2002-2834 A 20020607 MO 2003-MJ717 W 20030606

MAKEAT 140:27027

Title compds: I |X=0, S, alkyl, amino, Y = amino, O, S, alkyl; Z=00 CS, inino, SO, SO3; Rl=B, alkyl, alkylosy, etc.; Rl=alkyl, alkenyl, alkyml, ecc.; Rl=B, alkyl, alkylamino, alkylalkoxy, etc.; Rl=B,

chypit, etc., N - 5, allyl, allylaton, thylaton, etc., N - 5, allyl, allylaton, etc., N - 5, allyl, allylaton, etc., allylato

23814-14-4 CAPLUS 1E-Benzanidarole-5-carboxylic acid, 2,3-dihydro-2-oxo- (CA INDEX NAME)

67014-36-2 CAPUS 2E-Zenrunidarol-2-one, 5-anino-1,3-dihydro-6-methyl- (CA INDEX NAME)

- AREMEN 17 OF 20 CAPLUS COFFRIGHT 2009 ACS on STN (Continued) [Therapeutic use); BIOL (Biological study); FREP (Preparation); USES | [Ges] | [preps. of substituted beninidatoles which inhibit the optobine or biol.activity of macrophage migration inhibitory factor [HT]) | S458-13-2 CMJUS | [CAMPUT | CAMPUT | CAMPU

58089-25-1 CAPLUS 1E-Benzimidarole-1-carboxylic acid, 2,3-dihydro-2-thioxo- (CA INDEX

RN 100253-32-5 CAPLUS CN 2E-Renzinidasol-2-one, 1.3-dihydro-5-pentyl- (CA INDEX NUME)

106429-57-6 CAPUUS 18-Feminidatole-5-carboxylic acid, 2,3-dihydro-2-oxo-, methyl ester (CA NDEX NAME)

634602-82-7 CAPLUS IB-Beninidarole-5-carboxylic scid, 2,3-dihydro-2-oxo-, pentyl exter (CA IRDIX NUML)

LO AMBMER 17 OF 20 CAPLUS COPYRIGHT 2000 ACS on STN (Continued)

83573-62-0 CAPUJE 2B-Benzimidazol-2-ome, 1,3-dihydro-5-methyl-6-mitro- (CA INDEX NAME)

RM 634602-85-0 CAFLUS CB 1-Serine, N-[(2,3-dshydro-2-oxo-1B-benzimidazol-5-y1)carbomyl]-, methyl exter (CA REMEX RAME)

634602-87-2 CAPLOS L-Phenylalanine, N-[(2,3-dihydro-2-oxo-18-benzimidazo1-5-y1)carbonyl]-nethyl erier (CA IMBEK NAME)

36894-35-2P 58089-25-1P 100253-32-5P 100423-37-6P 200420-38-7P 634602-38-1P 634602-38-3P 634602-38-3P 634602-38-3P 634602-38-3P 634602-38-3P 634602-38-3P 634602-38-3P 634602-39-3P 634602-39-3P 634602-39-3P 634602-39-3P 634602-39-3P 634602-39-3P 634602-39-3P 634602-39-3P 634602-39-4P 634602-(Pharmacological activity); SPN (Synthetic preparation); TEU

LO ANSWER 17 OF 20 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

634602-83-8 CAPLUS 18-Benzinidarole-5-carboxylic acid, 2,3-dihydro-2-owo-, 2-(2-hydroxyethoxy)ethyl exter (CA INDEX NAME)

634602-84-9 CAPLUS 18-Benzimidazole-5-carboxylic acid, 2,3-dihydro-2-oxo-, ethyl ester (CA NDEX NME)

EN 634602-88-3 CAPLAS CN L-Phenylalanine, N-[42,3-dihydro-2-oxo-18-benzinidazol-5-yl)carbonyl]-(CA INDEX NAME) Absolute stereochemistry

AREMER 17 OF 20 CAPLUS COPTRIGHT 2008 ACS on STN (Contamond)

JR-Benzinidarole-5-carkoxamide, N-(2-(3,4-dihydroxyphenyl)ethyl)-2,3-dihydro-2-oxo- (CA INDEX NAME)

634602-90-7 CAPLUS 1E-Penninidarole-5-carboxylic acid, 2,3-dihydro-2-thioxo-, pentyl ester ICA IDENS MAME)

634602-91-8 CAPLOS \$6-Glucopyranose, 2,3,4,6-tetrascetate 1-(2,7-dlubydro-2-oxo-18-benzinidazole-5-carboxylate) (CA INDEX NAME)

-one, 5-bromo-1,3-dihydro-6-methyl- (CA INDEX NAME)

AMBMER 17 OF 20 CAPLUS COFFRIGHT 2008 ACS on STN (Continued) (CA INDEX NAME)

us 5-carboxinidanide, N-butyl-2,J-dihydro-2-oxo- (CA INDEX

REFERENCE COUNT: 17 THERE ARE 17 CITED REFERENCES AVAILABLE POR 7818 RECORD. ALL CITATIONS AVAILABLE IN THE RE TORMAT

LS AMSMER 17 OF 20 CAPLUS COPTRIGHT 2008 ACS on STN (Continued)

634692-93-0 CAPLUS 2B-Benzumidarol-2-one, 1,3-dihydro-5-hydroxy-6-methyl- (CA INDEX NUME)

FN 634602-94-1 CAPARS CR 2B-Benzinidarol-2-one, 1,2-dihydro-5-tridecyl- (CA INDEX NAME)

634602-95-2 CAPLOS 28-Benzinidazol-2-one, 4,5,7-tribromo-1,3-dihydro-6-methyl- (CA INDEX

634602-96-3 CAPLUS Acetanide, N-(2,3-dihydro-6-methyl-2-oxo-18-benrimidarol-5-yl)-2-(2-pyrimidinylthio)- (CA INDEX NAME)

624602-97-4 CAFLUS 18-Benzinidazole-5-carbothiolo acid, 2,3-dihydro-2-oxo-, 8-pentyl ester

FLOS CONTRIGET 3000 ACS on STM 138371452 CALLOS 138371452 CALLOS 138371453 CALLOS Exclusive the state of the protecting tixes for Machiner, Mac 2 government; GAS COMMITTED 1001, 79 pp. Date of the state of the state of the state of the COMMITTED 1001, 79 pp. Fatest Explish

INVENTOR(S): PATENT ASSIGNEE(S): SOURCE:

DOCUMENT TYPE: LANGUAGE: FAMILY ACC. NUM. COUNT: PATENT INFORMATION:

A1 20030424 U8 2002-155924 2002052: U8 2001-293835P P 2001052: US 20030078190 PRIORITY APPLE. IMPO.:

PRODUCT PATRIC. 1870.

3 Methods and parameterization company, are provided for generalization of the control o

129481-59-7 CAPLES
1B-Benzandszole-7-carboxylic acid,
2-ctboxyl-1-[2*-[25*-[45*-4ctxzol-5-yl)[1,1*-bipbenyl]-4-yl]sethyl]- (CA

[4470]-48-4 CARLES [3,3"-Buphany]]-2-carboxylsc acid, ["=(2,4"-dimethyl-2"-propyl[2,6"-bi-18-benzinidazol]-1"-yl)methyl)- (CA BERK 19ME)

144'03-40-4 CARLOS [1],1'-Baphenyl'-2-carboxylic acid, 4'-[4],4'-dunethyl-2'-propyl[2,6'-bi-18-benzimidazol]-1'-yl)methyl}- (CA HDDEX NAME)

LO AMBMER 18 OF 20 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

LS ANSWER IS OF 20 CAPLUS COPTRIBET 2008 ACS on STN

PAGE 2-A

NUS COFFRIGET 2008 ACS on STN 1999-819234 CAPLUS 132:59191 Therapouluc methods employing disulfide derivatives

dithiocarbanates and compositions useful therefor Lai, Chisp-Sany Warzilev, Waszil Medinox, Jac., CBA PCT Int. Appl., 102 pp. Fatent Lancz English 3 3 3

DOCUMENT TYPE: LANGUAGE: FAMILY ACC. NON. COUNT:

TENT		INFOR.	NO.71	CRI:														
												LICAT						
	60	9966	918			8.1		1999	1229		WO :	1999-	0814	237		- 3	9990	625
		56 +	AE.	AL.	MM.	AT.	241.	82.	BA.	RB.	BO.	BB.	BY.	CA.	CH.	CN.	cu.	CZ.
												CN,						
												LS.						
												SD.						
												73.		,				,
		256										234		DE.	CU.	CV.	DE.	DX.
												NI.						
		0000	242	cary	0017	2017	Om,	2207	0305	1407		, TD, 1998-	1030	20			0000	000
- 3	20		050			٠.		1000	1000		00	1999-	10.26	27		- 1	2200	000
- 1	0	2333	020			- 0.1		1777	1227		· ·	1999-		020		- 3	2770	022
- 1	vo.	7626	119			- 2.		2000	0110		<i>no</i> .	1535-	4111	2			2220	622
,	w	10.20	00			B.2		2003	0103									
- 1	EP.											1999-						
		R.			CH,	DE,	DE,	ES,	FR,	GB,	GR,	, IT,	LI,	LU,	NL,	SI,	MC,	PT,
			IE,															
- 3	TP.	2002	5184	41		7		2002	0625		JP :	2000-	5556	04		- 3	9990	655
- (18	6316	502			B1		2001	1113		08 3	2000-	5656	66		- 2	0000	505
IORI	m	APP.	LSI.	IMPO	- 5						08	1998-	1036	39		VS 1	9980	623
											wo :	1999-	0514	237		и 1	9990	622

OTHER SOURCE(S): NARPAT 132:59191
AB The invention provides a dithiocarbanate disulfide dimer useful in various

The promotion processor is a contract of the c

- MEMER 19 OF 20 CAPLUS COFFEIGHT 2008 ACS on STN (Continued) study, unclassified); TBU (Therapeutic use); BIGL (Biological study);
- en; (dithioparbamate digulfides, alone or with other agents, for
- [dithiocarbanate disulfides, alone or with other agents, for therapeutic use) 13422-31-0 CMPLUS (chimanuda, Co-hydroxy-, f-(dihydrogen phosphate), inner malt, 3*-exter with (5.6-dimethyl-1-4-D-ribofuranosyl-1H-benzinidarole-MS)

PAGE 1-A

RIGINAL REFERENCE NO. :

INVENTOR(S): PATENT ASSIGNED (S) :

DOCUMENT TYPE:

LANGUAGE: FAMILY ACC. NUM. COUNT: FATENT INFORMATION:

PATENT NO. KIND DATE APPLICATION NO. DATE | MPECONTON | MIDS | MPECONTON NO. | MATE | WO 9805327 AU 1997-38990 US 1996-23165P 19970722 P 19960805 PRIORITY APPIN. INFO.: MO 1997-0813343 N 19970722

- * STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY AVAILABLE VIA OFFLINE PRINT * This invention is directed to compound of formula (1) ring $\lambda = 010$, 011;

LO ANSMER 19 OF 20 CAPLUS COPYRIGHT 2000 ACS on STN (Continued) PAGE 2-A

THERE ARE 3 CITED REFERENCES AVAILABLE FOR RECORD. ALL CITATIONS AVAILABLE IN THE RE

- ARREN 10 72 CANADA CONTAINT DOWN AND AS THE CONTAINES 10 AT 25 TH OF 15 IL 22 Electron (0, 12 IL 20 Electron (0, 12 IL 2
- modulated by inhibiting THF, e.g., joint inflammation, atthritis, rhowarded arthritis, rhowarded arthritis, rhowarded arthritis, pengle, special policy and experience and experience and experience and experience are experienced and experience and
- diseas, applicated pupus exploits, those gloverinequists, self-ments applying the property of the property of
- smally, militaries described and a second militaries of the second mili

- ARRAGE 20 OF 20 CAPLUS COFFRIGHT 2008 ACS on STN (Continued) EL: ECT (Reactant); STN (Synthetic preparation); FREF (Preparation); EACT (Reactant or reagent) ||Description or respect| | (props. of substituted aron. compds. as inhibitors of temor mecrosis | factor and cUAP phosphodiexterase) | 201287-03-8 CAPARS | IR-bentinidarole-4-enricoxylic acid, 7-methoxy-2-(methoxymethyl)- (CA

201287-04-9 CAPLUS 1E-Eeszinidszole-é-csrboxylic acid, 7-methoxy-2-phenyl- (CA INDEX NAME)

201287-05-0 CAPLUS 15-Tearinidarole-4-carboxylic acid, 7-methoxy-2-(2-phenylethyl)- (CA NEDIX NUML)

201287-11-8 CAPLUS 1E-Bearinidarole-4-carboxylic acid, 7-methoxy-2-{(4-methoxyphenoxy)methyl)- (CA INDEX NAME)

NN 201297-14-1 CAPLUS

LO ANSMER 20 OF 20 CAPLUS COPYRIGHT 2000 ACS on STN (Continued)

201287-08-3 CAPLUS 1B-Benzimidarole-4-carboxylic acid, sthoxy-2-[(4-methoxyphenyl)methyl]-(CA INDEX NOME)

201287-09-4 CAPLUS 1B-Benzinidarole-4-carboxylic acid, 2-(1,2-diphenylethyl)-7-methoxy- (CA NDEX NDMS)

201287-10-7 CAPLUS 1R-Benzimidazole-4-carboxylic acid, 7-methoxy-2-(2-phenylpropyl)- (CA

ANSMER 20 OF 20 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
18-Benzimidazole-4-exrboxylle acid,
7-methoxy-2-(3-methoxy-1-phenylpropyl)- (CA INDEX NAME)

201287-15-2 CAPLUS 18-Benzimidazole-4-carboxylic acid, 2-[[4-cyanophenyl]methyl]-7-methoxy-(CA INDEX NUME)

201287-16-3 CAPLUS 1B-Benramidarole-4-carboxylic acid, 7-methoxy-2-[[4-(3-pyridinyl)phenyl]methyl]- (CA INDEX NAME)

L8 ARSMER 20 OF 20 CAPLUS COPTRIGHT 2008 ACS on STR (Continued)

201287-18-5 CARLUS 1E-Benzumidarole-4-carboxylic acid, 7-methoxy-2-(methoxyphenylmethyl)-

201287-20-9 CAMPLUS 18-Bennimidarole-4-carboxylic acid, 7-methoxy-2-methyl- (CA INDEX NAME)

201287-21-0 CAPLUS 18-Beminidarole-4-carboxylic acid, 7-methoxy-2-(phenoxymethyl)- (CA IMEXX NME)

ANSWER 20 OF 20 CAPLUS COFFRIGHT 2009 ACS on STN (Continued) 12-Benzimidazole-4-carboxylic acid, 7-methoxy-2-(methoxymethyl)-, methyl ester (CA INDEX NEWS)

201287-28-7 CAPLUS 18-Benzinidazole-4-carboxylic acid, 7-methoxy-2-phenyl-, methyl ester

201287-29-8 CAPLUS IE-Benzinidarole-4-carboxylic scid, 7-methoxy-2-(2-phenylethyl)-, methyl exter (CA IMMEX NAME)

201287-30-1 CAPERS IE-Benramidarole-4-carboxylic acid, 7-methoxy-2-(phenylmethyl)-, methyl eater (CA NUMEX NAME)

L8 ANSMER 20 OF 20 CAPLUS COFFEIGHT 2008 ACS on STN (Continued)

NN 201287-23-2 CAPLUS CN 18-Benzimidazole-7-carboxylic acid, 2-(phenylmethyl)- (CA INDEX NUME)

INDEX NAME)

201287-25-4 CAPLUS 1B-Benzinidazole-6-carboxylic acid, 2,7-dimethoxy- (CA INDEX NAME)

NN 201287-27-6 CAPLUS

ANSWER 20 OF 20 CAPLUS COPYRIGHT 2008 ACS on STN (Continues)

201287-31-2 CAPLUS 1R-Benzinidarole-4-carboxylic acid, 7-methoxy-2-(1-phenylethyl)-, methyl ester (CA IMBEX NAME)

201287-32-3 CAPLUS 1H-Benzimidazole-4-carboxylic acid, 7-methoxy-2-[(4-methoxyphenyl)methyl]-, methyl ester (CA INDEX NAME)

201287-33-4 CAPLOS
3 IB-Benzinidazole-4-carbonylis acid,
(opolobenylphenylmethyl)-7-methony-,
methyl ester (CA INDEX NAME)

201 201287-34-5 CAPACE CH 1R-Bentundarole-4-carboxylic scid, 2-(1,2-diphenylethyl)-7-methoxy-methyl sate (CA 1909S NAME)

P22 201287-35-6 CAPLUS
CN 18-Benzumidazole-4-carboxylic acid, 7-methoxy-2-(2-phenylpropyl)-, methyl ester (CA INEXX MAE)

NS 201287-36-7 CAPLUS CB 18-Remaindatole-4-caxboxylic acid, 7-pethony-2-[(4-methoxyghenoxylmethyl)-, nethyl ester (CA INDEX NAME) LO ANSMER 20 OF 20 CAPLUS COPYRIGHT 2000 ACS on STN (Continued)

FR 201287-37-8 CAFLES CB 18-Benzimidatole-4-carboxylic acid, 7-methoxy-2-(1-phenylbutyl)-, methyl ester (CA IREAC NAME)

R 201287-38-9 CAPLUS
B 18-Bennimidatole-4-camboxylic acid, 2-[(4-brocophenyl)methyl]-7-methoxy-,
methyl ester (CA HOREX NAME)

RE 201287-39-9 CAPLUS 28 18-Benzimidazole-4-carboxylic acid, 7-methoxy-2-(3-methoxy-1-phenylpropyl)-, methyl ester (CA INDEX NAME)

18 ANSWER 20 OF 20 CAPLUS COPTRICKT 2009 ACS on STN (Continued

222 201287-40-3 CAPLUS
CR 1R-Reminidatole-4-carboxylio acid,
7-methyloxy-2-(12-nethyxyphenyl)nethyl)-, nethyl ester (CA INDEX NAME)

333 201287-41-4 CAPLUS CD 1E-Benzamidasole-4-oxriboxylio acid, 7-methowy-2-[(2-nethoxyphenoxy)nethyl]-, nethyl ester (CA INDEX NAME)

RB 201287-42-5 CAPAUS TB 18-Pensunidazole-4-carboxylic acid, 7-methoxy-2-methyl-, methyl ester TROEX NAME) LO ANSWER 20 OF 20 CAPLUS COPTRIGHT 2000 ACS on STN (Contanued)

FR 201287-43-6 CAPLUS
CN 18-Benzimidarole-4-carboxylic acid, 7-methoxy-2-(phenoxymethyl)-, methyl ester (CA INDEX NAME)

RH 201287-44-7 CAPLUS
CS HB-Benrimidarole-4-oarboxylic acid, 2-cyclopentyl-7-methoxy-, methyl
ester
(CA INDEX NAME)

PB 201287-45-8 CAPLUS CP 18-Denzinidarole-7-curbonylio acid, 2-(phenylmethyl)-, methyl ester (CA IMDEX ROME)

201287-67-4 CAPLNS 1R-Pannimidarola-4-carboxylic acid, 2-cyclopentyl-7-methoxy-1-methyl-, methyl ester (CA INDEX NAME)

201287-68-5 CAPLUS 18-Reminidazole-7-carboxylis acid, 2-cyclopentyl-4-methoxy-1-methyl-, methyl seter (CA INDEX NAME)

ANSWER 20 OF 20 CAPLUS COFFRIGHT 2009 ACS on STN (Continued)

201287-76-5 CAPLUS 1R-Bezishdarole-4-carboxylic acid, 2-[(4-cyanophenyl)methyl]-7-methoxy-, methyl seter (CA INDEX NAME)

201287-77-6 CAPLIS
1E-Benzinidazole-4-carboxylio acid,
7-methoxy-2-[4-(3-pyxidinyl)phenyl]nethyl]-, methyl ester (CA INDEX

201441-55-8 CARADS 1B-Benilmidatole-4-acetic acid, 7-methoxy-2-(methoxymethyl)- (CA INDEX NAME)

LO ANSMER 20 OF 20 CAPLUS COPYRIGHT 2000 ACS on STN (Continued)

201287-69-6 CAPLES 1B-Benimidazole-6-carboxylic acid, 2,7-dimethoxy-, methyl exter (CA RDEX NOBL)

201287-74-3 CAPLES 1B-Benzimidazole-(-carboxylic acid, 7-methoxy-2-(methoxyphenylmethyl)-, methyl estr (CA INDEX RAME)

201287-75-4 CAPLUS
1B-Benzinidazole-4-carboxylic acid, 7-methoxy-2-(3-pyridinyl)-, methyl estex (CA IMBEX NAME)

LO ANSWER 20 OF 20 CAPLUS COPYRIGHT 2000 ACS on STN (Continued)

203441-56-9 CAPLUS IN-Benzinidarok -4-carbomyl chloride, 7-methoxy-2-(methoxymethyl)- (CA

203441-57-0 CAPLUS 1B-Benzinidazole-4-carboxylic acid, ryclohesylphenylmethyl)-7-methoxy-(CA INDEX NAME)

203441-58-1 CAPLUS IB-Benzumidarotic-4-carboxylac acid, 7-methoxy-2-(1-methylethoxy)- (CA PREEN NUMBER)

18 MEMBER 10 OF 10 CAPEUS COFFRIGHT 1008 MCS om STN (Continued) 92 301441-59-2 CAREUS CI IN-Continuidatole-4-carboxylic acid, 7-methoxy-2-(1-methylethyl)-, methyl eater (CA IMMEX NAME)

REFERENCE COURT: 1 THESE AME 1 CITED REFERENCES AVAILABLE FOR THIS RECORD, ALL CITATIONS AVAILABLE IN THE RE TORRAT

=> log y
COST IN U.S. DOLLARS

SINCE FILE ENTRY
ENTRY
SESSION
119.88 298.45

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)
CA SUBSCRIBER PRICE

SINCE FILE ENTRY
SESSION
-16.00 -16.00 -16.00

STN INTERNATIONAL LOGOFF AT 13:12:14 ON 18 NOV 2008